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INTRODUCTION Chemoprevention is the use of natural or synthetic agents to inhibit 
either the initial development or the further progression of early lesions. 
Chemoprevention of lung cancer aims to decrease lung cancer morbidity and mortality, 
especially for former smokers. Many synthetic and natural compounds have been 
investigated for their potential chemopreventive efficacy. Conventional administration 
of these compounds (especially oral administration) is convenient, but may potentially 
result in adverse side effects. Aerosol delivery, on the other hand, offers many 
advantages over conventional routes of administration for diseases of the respiratory 
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tract and the lungs. These advantages include the extensive pulmonary surface area 
available for drug deposition, the avoidance of first-pass metabolic degradation by the 
liver and/or intestines, the noninvasive nature of administration, and the localized effect 
of low doses of drugs, all of which lead to a rapid response with fewer systemic side 
effects. The efficacy of a given drug via aerosol administration depends on many factors 
such as particle size distribution, total particle mass concentration, and the 
physiochemical properties of drug particles. Genetically-engineered mice play an 
important role in drug screening and preclinical studies. However, because mice have 
much smaller lungs than those of human beings, the lung deposition data attained for 
humans cannot be applied to the mouse. Hence few studies have focused on particle 
deposition in the mouse lung. It is thus necessary to measure the mass deposition of 
particles in the mouse lung. 
METHOD A spray-drying process was used to study the inhibitory effects of potential 
chemopreventive agents on carcinogen-induced tumors in the A/J mouse. The 
carcinogen in the studies was benzo[a]pyrene, unless otherwise specified. Synthetic and 
natural compounds were investigated individually or in combination. The compounds 
were aerosolized with a custom-built Collison atomizer. The resultant drug aerosols 
were delivered to the mice that were retained in a nose-only exposure chamber. Four 
small molecular inhibitors (gefitinib, erlotinib, lapatinib and wortmannin), and four 
natural agents (resveratrol, caffeine, anthocyanins, and protocatechuic acid), were 
considered as examples of single agents. Gefitinib and erlotinib were delivered in an 
aerosol form to reduce the cutaneous side effects. Lapatinib and wortmannin were each 
administered both via aerosol and oral gavage to compare the efficacy and toxicity as 
they were administered via different routes. Resveratrol was evaluated in two models 
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with either vinyl carbamate or benzo[a]pyrene as the carcinogen. It was delivered via 
aerosol to avoid fast clearance in the blood before it reached the lung. Caffeine was 
delivered in aerosol to assess only its inhibitory effects and to avoid its negative effects 
on body weight. Anthocyanins were delivered via aerosol due to their poor 
bioavailability. Protocatechuic acid is a metabolite of anthocyanins and was also 
delivered via aerosol for comparison with anthocyanins. The combinations of 
aerosolized budesonide (a synthetic glucocorticoid) and dietary polyphenon E (a 
well-defined mixture of green tea extract) was discussed as one example of the 
combinational treatment.  
In addition to the bioassays, drug deposition in the mouse lung was evaluated for both 
polydispersed and monodispersed drug particles for a better understanding of the 
delivery process and for future applications. Gefitinib was selected as the model agent. 
Polydispersed gefitinib particles were generated with the Collison atomizer used in the 
animal studies. Monodispersed particles were generated using the single-capillary 
electrospray technique. Lung and blood samples were harvested immediately after the 
aerosol treatment. The lung and plasma levels of gefitinib were measured with varied 
solution concentrations, exposure durations, and particle sizes. The aerial mass 
concentration in the chamber was also measured to estimate the doses.  
RESULTS Aerosolized erlotinib (5 mg/ml) did not inhibit tumor multiplicity but 
reduced tumor load by 63.8% (P < 0.05). Aerosolized gefitinib in three separate doses 
(5, 10, and 15 mg/ml) inhibited tumor multiplicity by ~30% for all three doses when the 
tumors were induced by one dose of benzo[a]pyrene (100 mg/kg body weight), but the 
results were not statistically significant. Aerosolized gefitinib showed consistent 
inhibitory effects on tumor load, and the inhibition rate increased as the dose increased. 
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The tumor load was reduced by 39.0%, 46.2%, and 56.4% (P < 0.05) for 5, 10, and 15 
mg/ml gefitinib solutions, respectively. The highest dose (15 mg/ml) of gefitinib was 
repeated in mice whose tumors were induced by two doses of benzo[a]pyerene (100 
mg/kg body weight, one week apart) and it inhibited both tumor multiplicity (by 49.8%, 
P < 0.001) and tumor load (by 57.0%, P < 0.001). No visible skin alteration was 
observed in mice treated with aerosolized gefitinib or erlotinib. Both aerosolized 
lapatinib (50 mg/ml) and orally-administered lapatinib (100 mg/kg body weight) 
showed inhibitory effects. Aerosolized lapatinib reduced tumor multiplicity by 39.6% (P 
< 0.05) and tumor load by 41.7% (P < 0.05). Orally-dosed lapatinib reduced tumor 
multiplicity by 37.6% (not significant) and tumor load by 42.4% (P < 0.05). At the 
current doses of lapatinib, no adverse side effect was observed in either the aerosol 
group or the orally-dosed group. Wortmannin showed striking inhibitory effects via 
aerosol inhalation and per os. Oral wortmannin (1.0 mg/kg body weight) inhibited 
tumor multiplicity by 85.5% (P < 0.001) and tumor load by 77.9% (P < 0.05). In the 
same model, aerosolized wortmannin (2.0 mg/ml) inhibited tumor multiplicity by 50.8% 
(P < 0.05) and tumor load by 79.7% (P < 0.05). Despite the efficacy of oral wortmannin, 
the accompanying systemic adverse effects were not negligible. Reduced body weight 
and death were observed in the orally-dosed mice, but not in the aerosol treated mice. 
Thus, aerosolized wortmannin was evaluated a second time in the bioassay with two 
doses of benzo[a]pyrene, and it was found to reduce tumor multiplicity and tumor load 
by 66.7% (P < 0.001) and 80.4% (P < 0.0001), respectively, with a slight decrease in 
body weight. Resveratrol inhibited the proliferation of cells in the human lung cancer 
cell lines A549 and H1129, which indicates that resveratrol could possibly be an 
effective inhibitor of human lung cancer. Aerosolized resveratrol was shown to inhibit 
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the tumor load in both vinyl carbamate- and benzo[a]pyrene-induced models. The 
decrease in tumor load was 26.3% (P < 0.05) and 36.0% (P < 0.01) for 7.5 and 15 
mg/ml solutions, respectively, in the vinyl carbamate-induced model. In the 
benzo[a]pyrene-induced model, aerosolized resveratrol (15 mg/ml) significantly 
reduced tumor multiplicity by 37.1% (P < 0.05) and tumor load by 72.0% (P < 0.01). 
Pharmacokinetic studies showed that more resveratrol was delivered to the lung by 
aerosol inhalation than by oral gavage. Aerosolized caffeine (10 mg/ml) inhibited tumor 
multiplicity by 31.9% (P < 0.05) and tumor load by 44.3% (P < 0.05) without causing a 
reduction in the body weight gain, in contrast to the orally-administered caffeine, which 
did cause body weight loss. Aerosolized protocatechuic acid (12 mg/ml) reduced tumor 
multiplicity by 47.8% (P < 0.05) and tumor load by 44.9% (P < 0.05). However, the 
inhibitory effects of anthocyanins (5 mg/ml, extracted from black raspberries) were 
marginal (14.5% on the tumor multiplicity and 30.4% on the tumor load, not 
significant).  
The particle deposition in the mouse lung was estimated using gefitinib as the model 
compound. For the Collison atomizer, the aerosol mass concentration in the exposure 
chamber increased linearly from 12.3 to 179.8 μg/L as the solution concentration 
increased from 1 to 50 mg/ml. The lung and plasma levels of gefitinib increased 
monotonically with increased solution concentration and exposure time, and the 
concentration in the lung was much higher than that in the plasma. The deposition 
efficiency is defined as the ratio of the mass deposited in the lung to the dose, and it is a 
function of particle size. In general, monodispersed particles have a higher delivery 
efficiency than polydispersed particles. For polydispersed particles, the 2.5 mg/ml 
solution (with a mass mean aerodynamic diameter, MMAD, at 120 nm) had the highest 
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efficiency. For monodispersed particles, 100 nm particles showed the highest deposition 
efficiency.  
CONCLUSIONS Aerosol delivery is a promising approach for the chemoprevention of 
lung cancer. Many natural and synthetic compounds showed inhibitory effects on 
benzo[a]pyrene-induced lung tumorigenesis in A/J when they are delivered via aerosol 
inhalation. In contrast to oral administration, aerosol delivery of the agents mitigated 
systemic toxicities with comparable inhibitory effects and improved the efficacy of 
some agents by increasing their bioavailability in the lung. The current aerosol delivery 
system was characterized and the mass deposition in the mouse lung was positively 
correlated with both the solution concentration and the exposure time. Aerosols with an 
MMAD around 100 nm may have the highest delivery efficiency, for both 
polydispersed and monodispersed distributions.  
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Chapter 1 Introduction and Overview 
1.1 Introduction 
In 2012, lung cancer remained the leading cause of cancer death in the United States, 
accounting for 29% of cancer deaths in men and 26% in women (American Cancer 
Society, 2012). Based on its histopathological features, lung cancer is grouped into 
small cell lung cancer (SCLC; ~20%) and non-SCLC (NSCLC; ~80%). NSCLC is 
further divided into three subtypes: squamous cell carcinoma (~30%), adenocarcinoma 
(~50%), and large cell lung carcinoma (Wang et al., 2012). The 5-year survival rate for 
all stages combined is only 16%, despite improvements in surgical techniques and 
combined therapies (American Cancer Society, 2012). So far, an early detection method 
has not been perfected. Consequently, lung cancer is difficult to detect at an early stage 
and hard to cure at a developed stage. Unfortunately, there is a vast population at high 
risk of contracting this malignant disease, especially smokers and ex-smokers (Doll and 
Hill 1954; Herzog et al., 1997; Witschi et al., 1997a; Wingo et al., 1999). Therefore, it is 
imperative to prevent lung carcinogenesis. Although smoking cessation remains 
essential for lung cancer prevention, additional preventive and control strategies are still 
necessary to implement the intervention more completely, particularly for individuals 
already at risk due to past exposure.  
Chemoprevention is the use of natural or synthetic agents to inhibit the initial 
development or further progression of early lung lesions (Hong and Sporn, 1997). This 
concept has been applied to many types of cancers including, but not limited to, breast, 
colorectal, esophageal, skin, and lung cancer. In the case of lung cancer, it is more 
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effective to reduce the risk of developing lung cancer than to treat established or 
advanced disease (Wattenberg, 1985; Yang et al., 2002; William et al., 2009). Aside 
from the enormous benefit of preventing the malignant disease, there are three other 
reasons that lung cancer is an attractive target for chemopreventive strategies (Cohen 
and Khuri, 2002). First, lung cancer has a long latency period, about 20-30 years, 
between regular smoking exposure and the onset of the disease, which provides a long 
period of opportunity to initiate effective chemoprevention strategies to reverse 
premalignant lesions or even delay progression sufficiently to improve survival. Second, 
there are identifiable precursor lesions that provide a readily identifiable clinical 
endpoint to judge the effectiveness of chemoprevention. Last, but equally as important, 
there are numerous biomarkers available as potential intermediate endpoints for 
chemoprevention studies (Cohen and Khuri, 2002). Therefore, lung cancer is a 
promising target, and preventive intervention on carcinogenesis should be more 
effective than cancer treatment, considering the natural progression of lung cancer 
(Hecht et al., 2009). People at high risk of contracting lung cancer, mainly addicted 
smokers and ex-smokers, are the subjects for chemoprevention, as 90% of lung 
carcinogenesis is due to tobacco smoke exposure (Hecht et al., 2009). In the past 30 
years, many advances have been made in studies on the chemoprevention of lung 
carcinogenesis, which increases the feasibility that chemoprevention will be an effective 
approach for the control of human lung cancer (Hong and Sporn, 1997; Cohen and 
Khuri, 2002; Winterhalder et al., 2004; Vignot et al., 2005; Gray et al., 2007; Blesa et al., 
2008; Hecht et al., 2009). This progress includes understanding the mechanisms of 
carcinogenesis and the inhibitory effects of the drugs at the molecular level, developing 
suitable animal models such as transgenic mice, searching and screening for potentially 
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effective agents, developing biomarkers, and designing new drug delivery systems. 
In current studies of lung cancer prevention in animal models, drugs are usually 
administered through an oral route (for long term treatment) or an intraperitoneal (i.p.) 
injection, which is mostly for short term observation on xenografts in animals but is not 
suitable for lung cancer chemoprevention in humans. Targeted delivery of preventive 
agents at the site of action is desired to maximize their inhibitory effects on 
carcinogenesis and to avoid the exposure of other healthy organs and surrounding cells 
to the agents, especially those agents with poor metabolic profiles and systemic 
toxicities. The conventional oral route might not be effetive for the chemoprevention of 
lung cancer. Instead, the administration of drugs directly to the lungs via inhalation 
offers several advantages over oral administration. These include the extensive 
pulmonary surface area available for drug contact, the avoidance of first-pass metabolic 
degradation by the liver and/or intestines, and the noninvasive nature of administration. 
Inhalation also enables locoregional drug delivery of low doses of an aerosolized drug 
to its site of action for a localized effect, which leads to a rapid response with fewer 
systemic side effects (Hershey et al., 1999; Dolovich and Dhand, 2011; Zarogoulidis et 
al., 2012). Aerosol chemotherapy for lung cancer has been investigated in vitro, in 
animal models, and in human trials (Zarogoulidis et al., 2012). However, limited studies 
exist documenting the feasibility of delivering agents by inhalation for lung cancer 
chemoprevention. Our group evaluated the inhaled administration of polyphenon E (Fu 
et al., 2009), budesonide (Fu et al., 2011), and bexarotene (targretin) (Zhang et al., 2011) 
in a mouse lung cancer model and achieved significant inhibitory effects on lung 
tumorigenesis. We also reported higher concentrations of drugs in the lung and 
mitigated side effects regarding bexarotene when compared with oral administration 
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(Zhang et al., 2011). In this dissertation, the studies of the chemoprevention of lung 
carcinogenesis are extended to aerosol administration of small molecular inhibitors and 
more natural compounds to prevent primary lung tumors induced by the 
tobacco-derived carcinogen, benzo[a]pyrene, in the mouse model.  
Furthermore, studies on single agents offer limited insight into the chemoprevention 
of lung carcinogenesis. Tobacco smoke contains multiple lung carcinogens, toxicants, 
co-carcinogens, tumor promoters, and inflammatory compounds (Hecht et al., 2009), 
which play different roles in the initiation, promotion, and progression of lung cancer. 
Moreover, lung carcinogenesis is a complex mix of miscellaneous mutations and lesions 
at different stages of development (Yamaguchi and Perkins, 2012). Therefore, targeting 
one molecular pathway or step to inhibit carcinogenesis is difficult and may not always 
be possible. Accordingly, we reason that a logical combination of multiple agents that 
target different pathways can enhance the inhibition of lung tumorigenesis and reduce 
adverse side effects. To demonstrate this concept, I tested several combinational groups 
of agents and will discuss one of them in detail in Chapter 6. The combination of 
aerosolized budesonide, a synthetic glucocorticoid for anti-inflammation, and dietary 
polyphenon E, a well-defined natural mixture extracted from green tea, was investigated 
for their chemopreventive efficacy on lung carcinogenesis.  
Besides lung cancer prevention, pulmonary delivery of drug particles is also preferred 
for other diseases in the respiratory tract and the lung, especially for cystic fibrosis, 
asthma, and COPD (chronic obstructive pulmonary disease) (reviewed in refs: Sham et 
al., 2004; Kleinstreuer et al., 2008). Recently, drug-aerosol inhalation has also been used 
to deliver medicine, such as growth hormone, calcitonin, etc. (Siekmeier and Scheuch, 
2009) as a novel approach to systemic therapy. To maximize medical effectiveness and 
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to minimize the potential side effects, aerosol delivery of drugs must be targeted, which 
means delivering drug aerosols to the specified sites in the respiratory system. The 
desired sites are related to specific diseases. For example, regarding lung cancer 
treatment, adenocarcinomas are usually seen peripherally in the lungs, as opposed to 
small cell lung cancer and squamous cell lung cancer, which both tend to be centrally 
located. Therefore, for adenocarcinomas, most of the drug aerosol needs to be delivered 
to the peripheral airways, even to the alveoli. For small cell lung cancer and squamous 
cell lung cancer, most of the drug aerosol needs to be delivered to the central airways. 
For the chemoprevention of lung carcinogenesis, the drug aerosols need to cover the 
whole respiratory tract, since the types and the sites of tumors cannot be anticipated,.  
Table 1‐1 Comparison of Murine and Human Lung Anatomy (Fox et al., 2007) 
 Mouse Human 
Alveoli 38-80 μm 200-400 μm 
Diameter main bronchus 1 mm 10-15 mm 
Airway branching pattern Monopodial Dichotomous 
Diameter bronchioli 0.01-0.05 mm < 1mm 
Diameter terminal bronchioli 0.01 mm 0.6 mm 
 
The efficacy of a given drug delivered via aerosol administration depends on many 
factors, such as the physiochemical properties of the drug, the anatomy of the 
respiratory tract, and the airflow pattern in the lung airways. For a given drug, the 
particle size distribution is the most important property controlling the particle 
deposition. Genetically-engineered mice play an important role in drug screening and 
preclinical studies, while only limited studies have focused on particle deposition in the 
mouse lungs. The success or failure of pulmonary administration of drug aerosols in 
mouse models cannot be elucidated explicitly until we have a better understanding of 
the particle transport and deposition behavior in vivo. Because the mouse respiratory 
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system is much smaller than that of a human being (Table 1-1), the deposition data 
obtained for human respiratory systems should not be applied to the case of mice. It is, 
thus, necessary to measure the mass deposition of particles in the mouse lung. In this 
dissertation, the mass deposition of drug particles was measured for both polydispersed 
and monodispersed particles.  
Since no chemopreventive agent has been validated for lung cancer, more effort is 
needed to screen agents. Aerosol delivery may provide new opportunities to revive 
otherwise effective agents with adverse side effects and to increase the locoregional 
quantity of drugs in the lung. Additionally, characterization of the aerosol delivery 
system is also needed for data interpretation and system improvement. There are two 
major objectives of this dissertation:  
1. To study the chemopreventive effects of synthetic and natural compounds via 
aerosol administration, singly or in combination with another agent, in the 
mouse model. 
2. To evaluate drug particle deposition in mouse lungs. 
1.2 Dissertation Structure 
The whole dissertation contains eight chapters.  
Chapter 1 is a general introduction to the background, the motivations, and the 
objectives of this study.  
Chapter 2 is dedicated to reviews of three aspects. First, some evolved concepts of 
carcinogenesis and chemoprevention are reviewed, and the key factors in 
chemoprevention studies in animal models are discussed. Promising targets and agents 
in preclinical studies and clinical trials are only briefly discussed since there are many 
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incisive and comprehensive reviews on these topics. Second, agents that have been 
tested in mice for their chemopreventive effects via aerosol inhalation are reviewed as is 
progress achieved and lessons learned. Third, the advances in the aerosol delivery of 
drug particles to the mouse respiratory tract are reviewed. 
Chapter 3 introduces the experimental setup and the protocols of animal experiments 
used in this study. A complete list of agents and agent combinations that have been 
tested is presented.  
In Chapter 4 through Chapter 6, potential chemopreventive agents are evaluated via 
inhalation, either singly or in combination, in mice. Chapter 5 evaluates four small 
molecular inhibitors. First, aerosolized gefitinib and erlotinib, which target the tyrosine 
kinase domain of the epidermal growth factor receptor (EGFR), are examined for their 
inhibition on tumorigenesis in mouse lungs, and their toxicities are evaluated. Then, 
lapatinib, a novel dual inhibitor of both EGFR and Her2 (human EGFR type II, also 
known as Neu, ErbB2) is studied. Lapatinib was administered via both inhalation and 
oral gavage, and the comparative efficacy is noted. Last, a covalent inhibitor of 
phosphoinositide 3-kinase (PI3K), wortmannin, is used as a model drug to demonstrate 
the advantages of aerosol drug delivery. Wortmannin is a potent PI3K inhibitor, but it 
failed clinical translation due to drug-delivery challenges and toxicities. Wortmannin 
was delivered via both inhalation and oral gavage, and the efficacy and systemic 
toxicity are compared. Chapter 5 gives the results of the evaluation of four interesting 
natural compounds. Resveratrol, a phytoalexin from plants, and anthocyanins, dyes 
extracted from black raspberries, were delivered in the form of aerosols, because 
resveratrol has a fast clearance in the blood and anthocyanins have low bioavailability. 
Protocatechuic acid, as a major metabolite of anthocyanins and tea polyphenols, was 
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also studied to compare with anthocyanins. Caffeine, one component of tea extract and 
an interesting agent prevalent in our daily life, was also studied. In Chapter 6, the 
combination of aerosolized budesonide and dietary polyphenon E was studied.  
In Chapter 7, mass deposition of drug aerosols in mouse lungs is measured and 
discussed. Gefitinib was used as a model drug. The lung and plasma levels of the drug 
delivered via inhalation are correlated to the solution concentration, exposure duration, 
and particle sizes.  
In Chapter 8, the accomplishments of this dissertation are summarized. The issues 
and challenges in current studies are also discussed for future research efforts.  
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Chapter 2 Review 
This work focuses on the aerosol administration of synthetic and natural agents that 
may potentially be chemopreventive of lung carcinogenesis and drug particle deposition 
in the mouse lung. Thus, we will review several principles and current progress 
regarding these two topics. 
2.1 Chemoprevention of lung carcinogenesis 
2.1.1 Carcinogenesis 
Carcinogenesis is the process by which the growth, development, identity, and 
proliferation of normal cells becomes dysregulated and life-threatening, and is 
experimentally categorized in three broad stages – initiation, promotion, and 
progression (Wu et al., 2011).  
There are two important concepts regarding carcinogenesis: multistep carcinogenesis 
and the “field of cancerization”. The multistep carcinogenesis theory, which is 
supported by recent molecular findings (Gomperts et al., 2011), describes a stepwise 
accumulation of genotypic and phenotypic changes progressing through pre-invasive 
histological changes to invasive disease (Cohen and Khuri, 2002; Soria et al., 2003). 
The field of cancerization refers to areas of histologically normal-appearing tissue 
adjacent to neoplastic lesions that display molecular abnormalities, some of which are 
the same as those in tumors (Gomperts et al., 2011). Malignant lesions can develop from 
multiple genetically distinct clones in diverse areas, and lesions in one part of the 
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exposed area imply increased risks of developing cancer in other sites within the area 
(Soria et al., 2003; Gomperts et al., 2011).  
2.1.2 Chemoprevention 
Chemoprevention is defined as the use of pharmacologic or natural agents that inhibit 
the development of invasive cancer, either by blocking the DNA damage that initiates 
carcinogenesis or by arresting or reversing the progression of premalignant cells in 
which such damage has already occurred (Hong and Sporn, 1997). The essence of 
chemoprevention is intervention within the multistep carcinogenic process and 
throughout a wide field (Cohen and Khuri, 2002). The stepwise accumulation of 
precancerous alterations at the molecular level reflected in the macroscopic view is the 
latency period of cancer. The field of cancerization implies the uncertainty of the type 
and the location of tumors. Thus, chemoprevention aims to extend the latency period to 
a meaningful length to achieve a lifetime suppression of malignancy by targeting the 
whole epithelial surface of the respiratory tract with single or multiple chemopreventive 
agents. 
Before clinical trials are begun, the efficacy and safety of new agents should be 
validated in experimental models. Appropriate animal models are essential for cancer 
chemoprevention studies. To build a sound scientific premise for an animal bioassay 
that shows the efficacy of chemopreventive agents, we must consider three critical 
factors. First, we need an appropriate animal model for specific forms of cancer. Then 
we need an appropriate test agent (plausible mechanism, defined dose, route, and 
duration). Finally, we need biomarker(s)/intermediate lesions that can be evaluated to 
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provide insights into the mechanisms of the agent’s efficacy or toxicities. Since the 
analysis of biomarkers was not involved in this dissertation, the following review is not 
intended to cover this topic.  
2.1.2.1 Animal models 
Animal tumor/cancer models fall into three categories: (1) well-established 
chemically-induced; (2) spontaneous; or (3) transgenic (Steele and Lubet, 2010). The 
endpoint of an animal bioassay is not as controversial as that of clinical trials (Wu et al., 
2011) and is typically the tumor, which is the primary endpoint in most phase III clinical 
prevention trials. Experimental data of cell lines and animal models are the cornerstone 
of clinical trials and further development of chemopreventive agents. The animal 
bioassays not only provide evidence of agent efficacy, but also help to generate 
dose-response, toxicity, and pharmacokinetic data prior to clinical trials. An ideal animal 
model for chemoprevention testing should have the ability to assemble or approximate 
intermediate and cancerous lesions of human lung cancer both molecularly and 
histologically, and should bear similar genetic and epigenetic alterations to those found 
in humans. Besides, the animal model should “be capable of producing consistent tumor 
burden in greater than 60% of animals developing the endpoint (typically cancerous 
lesions) within a reasonable period of time (< 6 months)” (Steele and Lubet, 2010), and 
should have high predictive validity in humans. No current animal model is ideal, and 
better animal models are sought.  
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Table 2‐1 Carcinogen‐induced and genetically‐engineered animal models in current use for the 
screening and development of  lung  cancer  chemopreventive agents  (Steele  and Lubet, 2010; 
Wang et al., 2012; Dragnev et al., 2013) 
Species  Carcinogen/Genetic Modification Endpoint Measured 
Hamster  MNU  Squamous cell carcinomas 
Mouse 
B[a]P, NNK,  vinyl  carbamate, uracil, urethane, 
cigarette smoke 
Adenomas and adenocarcinomas 
Mouse  NTCU  Squamous cell carcinomas 
Mouse  TP53 mutants plus B[a]P or NNK Adenocarcinomas 
Mouse  Altered TP53 and GPCR5a knockout (NNK) Adenocarcinomas (no K‐ras mutation)
Mouse  Floxed Rb and p53 allele  Small cell lung cancer 
Abbreviations:  MNU,  methylnitrosourea;  NNK,  4‐(methylnitrosamino)‐1‐(3‐pyridyl)‐1‐butanone; 
NTCU, N‐nitroso‐tris‐chloroethylurea; B[a]P, benzo[a]pyrene; TP53, tumor protein 53 gene; GPCR5a, 
G‐ protein‐coupled receptor family C, group 5, member a gene; Rb, retinoblastoma protein. 
 
For testing potential lung cancer prevention agents, carcinogen-induced and 
genetically engineered animal models that are commonly used are summarized in Table 
2-1. The animal models in Table 2-1 represent all histological types of human NSCLC. 
A potential chemopreventive agent needs to be evaluated comprehensively for each lung 
cancer type in the relevant animal model. Transgenic animal models are not included 
in Table 2-1, but they are useful for studying the mechanism of carcinogenesis and 
chemopreventive agents, especially agents that act on specific molecular and cellular 
targets, because transgenic animal models bear certain genetic abnormalities which are 
similar to those found in humans, such as insertions, deletions, and mutations at targeted 
gene sites.  
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Figure  2‐1  Lung  adenoma  induced  by  one  dose  of  B[a]P,  100  mg/kg  body  weight, 
intraperitoneal  injection  (i.p.),  20 weeks,  A/J  female mouse with  normal  lung  as  control: A, 
gross view of lung with adenoma; B, gross view of lung with adenocarcinoma induced by vinyl 
carbamate,  0.32 mg per mouse,  i.p.,  20 weeks; C,  histopathology  of  lung  adenomas.  (Figures 
adopted from Wang et al., 2012) 
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In this dissertation, the mouse lung adenoma model in A/J mice (Figure 2-1) was used 
because it is efficient, consistent, and reliable. It provides helpful comparison since it 
has been frequently used in previous studies. In this model, lung adenomas (most 
harboring K-ras mutations) can be induced by various carcinogens such as vinyl 
carbamate, benzo[a]pyrene (B[a]P), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
(NNK), diethylnitrosamine, uracil mustard, and urethane. Among these carcinogens, 
B[a]P, NNK, vinyl carbamate, and urethane are related to cigarette smoke and are 
frequently used in animal models to simulate cancerous lesions normally caused by 
cigarette smoke in humans. A more relevant carcinogen is the cigarette smoke itself, 
which mimics the cancer induction process in humans by a complex mixture of 
chemicals. The doses and schedule of the carcinogens in each model listed in Table 2-1 
are described in detail (Steele and Lubet, 2010; Wang et al., 2012). 
2.1.2.2 Protocols 
 
Figure 2‐2 Commonly used Chemoprevention Protocols (Adopted from Wang et al., 2006) 
There are three frequently used protocols (Figure 2-2) for testing the efficacies of 
chemopreventive agents using A/J mice based on the agent’s mechanism of action and 
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the stages of tumor progression. In the complete protocol, intervention begins 1-2 weeks 
prior to carcinogenic initiation and continues thereafter until 20-24 weeks. This model is 
used to examine agents that either block carcinogen initiation and/or suppress tumor 
growth. However, only limited lung tumor progression from adenomas to 
adenocarcinomas occurs at 20-24 weeks, when animals are usually terminated. In the 
post-initiation protocol, intervention begins 2-3 weeks post-carcinogen initiation and 
continues until termination of the animals at 20-24 weeks. This model is used to 
determine tumor suppressing effects independent of tumor initiation, mimicing the 
status of ex-smokers who quit smoking and receive preventive treatment. In the tumor 
progression protocol, intervention begins 12-20 weeks post-carcinogen initiation and 
continues to approximately 30 weeks. This model is used to determine the effects of 
chemopreventive agents on progression from adenomas to carcinomas. The tumor 
progression protocol is more relevant to clinical chemoprevention trials in humans with 
tumor histology as the endpoint.  
2.1.2.3 Agents 
The identification of promising chemopreventive agents usually relies on three 
approaches: epidemiological studies that show a positive correlation between dietary 
patterns and the risk of developing cancer, such as β-carotene (Hennekens et al., 1996; 
Omenn et al., 1996); traditional and historical pharmacopeia that show antitumor effects 
clinically, such as Chinese herbal medicine (reviewed by Li et al., 2013); and a more 
targeted approach towards promising molecular and cellular targets, as reviewed by 
Thiery-Vuillemin A et al (2005).  
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Empirical approaches based on epidemiological data are unpredictable (Sporn and 
Suh 2012). The efficacy and toxicities of agents that correlate with a reduced cancer risk 
should be validated in experimental models before they move on to clinical trials. 
Traditional prescriptions and therapies encounter similar or even problematic situations 
due to lack of statistical significance and convincing mechanisms. Many studies are 
testing the chemopreventive efficacy and toxicities of these agents in cell lines and 
animal models. These studies seek to determine the effective ingredients or active 
components, revealing the active mechanisms within the affected sites. Such agents are 
mostly naturally occurring, including nutrients or nutritional supplements from food and 
beverages, and compounds or complexes derived from animals, plants, herbs, etc. It is 
worth noting that a new trend in studying these agents focuses not only on the single 
“active” ingredient/compound, but also on the existence of other ingredients as a 
complex, such as (-)-epigallocatechin-3-gallate (EGCG) in polyphenon E (Fu et al., 
2009; Zhang et al., 2010), or herbs in Chinese medicine, used singly or in compounds.  
The most rational approach is to design and test potential chemopreventive agents 
that act on specific molecular and cellular targets (Sporn and Suh 2012). Examples of 
these targets or pathways include retinoid receptor signaling, mutations in and 
overexpression of transmembrane receptors (epidermal growth factor receptor [EGFR] 
and insulin-like growth factor receptor [IGFR]), inflammation and inflammation related 
pathways (cyclooxyenase-2 [COX-2] and nuclear factor kappa-light-chain-enhancer of 
activated B cells [NF-κB]), angiogenesis (vascular endothelial growth factor [VEGF]), 
histone deacetylase, cyclin D1, etc. The emerging studies of targeted agents are 
accompanied by the accumulation of knowledge concerning carcinogenesis. Promising 
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targets and potential agents for lung cancer prevention have been reviewed extensively 
(Keith 2012; Sporn and Suh, 2012; Dragnev et al., 2013), thus, they will not be 
examined here.  
Only agents with the most potent efficacy and lowest toxicities in the cell line studies 
and animal models are considered to be tested in clinical trials. However, to date the 
clinical lung cancer prevention trials have shown minimal efficacy (Dragnev et al., 
2013). Thus, there is currently no validated agent for lung cancer chemoprevention. 
Previous and current lung cancer prevention trials are summarized in Table 2-2. The list 
of potential agents of for clinical lung cancer prevention trials is growing. Several 
agents that hold promise are suggested for future clinical trials, including myo-inositol, 
rapamycin, bexarotene, gefitinib and erlotinib (based on unpublished data in this 
dissertation), triterpenoid, etc (Keith 2012; Dragnev et al., 2013). More effort is needed 
to screen effective agents in preclinical animal studies and clinical trials.  
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Table  2‐2  Previous  and  current  clinical  trials  testing  potential  agents  for  lung  cancer 
chemoprevention (Keith 2012; Dragnev et al., 2013) 
Agents  Mechamism  Cohort Endpoint 
β‐carotene*  antioxidant  Current and former smokers Lung cancer incidence
Vitamine E*  antioxidant  Current and former smokers  Lung cancer incidence
Vitamine  A  and 
N‐acetyl cysteine* 
Retinoic acid agonist 
(RAR)/antioxidant   
Patients  who  had  received 
treatment  for  primary  lung 
cancer 
Recurrence,  death  or 
second lung cancer 
Anethole 
dithioethione* 
Increases 
glutathione‐S‐transf
erase and additional 
phase II enzymes 
Current  and  former  smokers 
with bronchial dysplasia 
Bronchial dysplasia 
Inhaled 
budesonide* 
Anti‐inflammation  Smokers with dysplasia Dysplasia histology 
Inhaled 
budesonide* 
Anti‐inflammation  Current  and  former  smokers 
with lung nodules 
Target nodule size 
Myo‐inositol†  PI3K inhibitor  Smokers  with  bronchial 
dysplasia 
Dysplasia histology 
Celexocib†  COX‐2  Current and former smokers Proliferative  marker 
Ki‐67 
Iloprost‡  Prostacyclin  analog; 
anti‐inflammation, 
anti‐proliferation 
Current and former smokers Endobronchial histology
Pioglitazone‡  PPARγ  Current and former smokers Endobronchial histology
Abrreviations:  COX‐2,  cycloxygenase‐2;  PPAR,  peroxisome  proliferator‐activated  receptor.  *：no 
effect; †: positive effect; ‡: ongoing trials. 
2.2 Aerosolized agent to avoid side effects 
The typical routes of administration include oral (in the diet, in the drinking water or 
by gavage), intravenous, intraperitoneal, and aerosol routes. Oral administration is 
preferred by humans for its convenience; however, aerosol administration hold major 
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advantages over other routes for agents with known toxicities to gastrointestinal organs 
and for those with poor metabolic profiles (i.e., they are rapidly metabolized and 
excreted) (Steele and Lubet, 2010).  
Aerosol administration may be as effective as other methods, or potentially increase 
the efficacy of multiple agents in animal models. For example, budesonide, a synthetic 
glucocorticoid, delivered by aerosol for very short periods of time, showed striking 
inhibitory effects in the lung adenoma model in A/J mice, both alone and combined with 
other orally-administered agents (Wattenberg et al., 1997; Wattenberg et al., 2000; Fu et 
al., 2010). Another example is Polyphenon E (PPE) and its active component 
(-)-epigallocatechin-3-gallate (EGCG), which are from green tea extract. Witschi et al 
(2004) did a pilot study on EGCG in A/J mice and showed that aerosolized (EGCG) had 
minor inhibitory effects. Yan et al (2007) and Fu et al (2009) investigated the inhibitory 
effects of PPE as a mixture (i.e., EGCG with other components) on lung tumorigenesis 
in A/J mice and found a consistent reduction in tumor load and multiplicity. Effective 
agents assessed in animal studies are candidates for clinical trials. However, inhaled 
budesonide failed in two Phase II clinical prevention trials (Lam et al., 2004; Veronesi et 
al., 2011). PPE in the diet showed similar inhibitory effects in a mouse model (Zhang et 
al., 2010). As an oral route is more convenient for humans, aerosol delivery is 
applicable but not necessary in the case of PPE.  
Aerosol delivery may be able to reduce the toxicity without losing efficacy. Two 
recent studies provided some evidence. Aerosolized bexarotene significantly reduced 
tumor multiplicity and tumor load without increasing total plasma cholesterol and 
triglyceride level compared with oral administration (Zhang et al., 2010). Inhaled 
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3-bromopyruvate (at a dose of 10 mg/ml) significantly decreased tumor multiplicaity 
and tumor load by 49% and 80%, respectively, without causing any liver toxicity 
(Zhang et al., 2012). Inhaled 3-bromopyruvate and bexarotene are promising agents for 
potential future clinical prevention trials. Thus, in the case of agents with associated 
toxicities when delivered by other methods, the aerosol approach is both applicable and 
necessary.  
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Table 2‐3 Testing conditions and efficacy of agents evaluated in previous work (Fu 2009, PhD 
dissertation) 
Agent  Route  Dose  Carcinogen 
Inhibition 
Multiplicity  Load 
PPE  Aerosol  15 mg/ml B[a]P 53 % 62 % 
PPE   
without EGCG 
Aerosol  15 mg/ml  B[a]P  20 %  22 % 
Gefitinib  Aerosol 
1 mg/ml
VC 
6 %  26 %   
5 mg/ml 6 %  33 %   
5 mg/ml
B[a]P 
38 %  39 %   
10 mg/ml 27 %  46 %   
15 mg/ml 33 %  56 %   
Erlotinib 
Aerosol 
1 mg/ml
VC 
0 %  25 %   
5 mg/ml ‐12 %  36 %   
Aerosol  5 mg/ml B[a]P 5 %  64 %   
Resveratrol 
Aerosol 
7.5 mg/ml
VC 
‐5 % 26 % 
15 mg/ml 7 % 36 % 
Aerosol  15 mg/ml B[a]P 37 % 72 % 
Budesonide    Aerosol 
1 mg/ml
B[a]P 
35 % 41 % 
6 mg/ml 42 % 72 % 
3 mg/ml 57 % 78 % 
PPE  Diet 1.5 w.t.% in diet B[a]P 27% 83%   
Budesonide 
+ PPE 
Aerosol   
+ Diet 
3 mg/ml + 
1.5 w.t.% in diet 
B[a]P *  58%    89%   
I3C  Diet 10 μmol/g diet B[a]P 36% 83%   
Budesonide   
+ I3C 
Aerosol   
+ Diet 
3 mg/ml + 
10 μmol/g diet 
B[a]P  42 %    85%   
Pioglitazone  Gavage  10 mg/kg B.W. B[a]P 6 %  63%   
Budesonide   
+ Pioglitazone 
Aerosol   
+ Gavage 
3 mg/ml + 
10 mg/kg B.W. 
B[a]P  55.5%    89.6%   
Abbreviations: PPE, polyphenon E; EGCG,  (‐)‐epigallocatechin‐3‐gallate; B[a]P, benzo[a]pyrene; VC, 
vinyl carbamate; I3C, indole‐3‐carbinol; B.W., body weight. The exposure duration of all the aerosol 
treatment was 15 min except that budesonide was given for 2 min.   
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To provide more candidates for clinical trials, more agents were evaluated with the 
rationale that the aerosol approach may revive agents in which the oral approach causes 
side effects or low bioavailability. Former work is presented in Table 2-3. The results 
and testing conditions are summarized. A part of the work for this dissertation is the 
extension and development of previous studies: gefitinib was evaluated again in order to 
verify the efficacy and toxicity; a pharmacokinetic study of resveratrol was conducted to 
explain the efficacy shown previously; and the three combination groups were repeated 
with lower doses of each single agent to weaken the overwhelming efficacy of 
budesonide.  
2.3 Particle deposition in the mouse lung 
Particle deposition in the mouse lung is studied for two purposes: toxicology and 
drug delivery. In contrast to the extensive studies on particle deposition in the human 
lung, there are only limited studies on particle deposition in the mouse lung. However, 
the data for the human lung cannot be applied to studies of the mouse lung due to the 
differences between human lungs and mouse lungs (Table 1-1). Despite the differences, 
the mechamisms of particle deposition in the respiratory system are the same for the 
human and the mouse. In general, five mechanisms are involved in the process of 
particle deposition in the lungs. The most important of these mechanisms are inertial 
impaction, sedimentation, and diffusion. Interception and electrostatic precipitation are 
generally less important mechanisms (Hinds, 1999). These mechanisms are directly 
related to the particle size (Hinds, 1999; Friedlander, 2000). Other factors that exert an 
impact on the delivery efficiency and particle deposition pattern in the respiratory 
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system include the physiochemical properties of aerosols, the anatomy of the respiratory 
tract, and the airflow pattern in the lung airways. When the animal model and the drug 
are fixed, the particle size distribution is the most important factor.  
It is challenging to measure the mass deposited in the lung and to map the deposition 
pattern in the central and peripheral lung because the mouse lung is much smaller than a 
human lung. Nevertheless, recent developments and advances in imaging, mass 
spectrometry, and data analysis tools have made it possible to evaluate the intra organ 
regional deposition patterns of pharmaceutical aerosols in preclinical species. Progress 
was achieved in two aspects. One was the development and validation of new methods 
with improvement in instrumentation, and the other was that the particle size was 
extended down to 150 nm for the particle size-deposition efficiency relationship. The 
achievements are summarized in Table 2-4. 
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Table 2‐4 Progress in particle deposition in the mouse lung 
Reference    Method    Conclusion   
Raabe et al., 1988   
Pharmacokinetics 
(Radioactive 
material)   
Enhanced  nasal‐pharyngeal  deposition  for  particles 
larger than 3 μm in aerodynamic diameter, with over 90 
percent nasal‐pharyngeal deposition for particles  larger 
than 5 μm. Conversely, pulmonary (alveolar) deposition 
approaches nil for the larger particles (0.27 μm, 45%)   
Zhang et al., 2008   
Pharmacokinetics 
(Difluoromethyl 
ornithine)   
The deposition fraction assessed by the assayed mass in 
the  lung  relative  to  the  calculated  inhaled  mass  was 
found  to  decline  exponentially with  particle  size  (150 
nm‐2.5 micron, MMAD).   
Marko‐VargaG  et 
al., 2011   
MALDI  Mass 
spectrometry, 
imaging mode   
This provided a method to measure the mass deposition 
in  the mouse  lung  although  the original  study did not 
deliver the drug in aerosols.   
Kuehl et al., 2012    SPEC/CT   
The  deposition  patterns  of  aerosols  between  0.5  and 
5.0 µm  (polydispersed, MMAD)  showed an  increase  in 
both  overall  and  peripheral  deposition  as  the  particle 
size decreased.   
Yi et al., 2012   
Fluorescent 
imaging ex vivo   
Aluminum  phthalocyanine  tetrasulfonic  acid  (AIPCS) 
particles  of  varied  sizes  were  used  to  measure  the 
particle distribution inside the lung and showed that the 
aerosol deposition is clearly linked to the lung function. 
 
Many efforts, including both computational modeling and experimental 
measurements, have been made to figure out the optimal size range for particle 
deposition in the mouse lung. One report tested particles ranging from 150 nm to 2.5 
µm (mass median aerodynamic diameter, MMAD) generated from an ultrasonic 
nebulizer, and by measuring the mass, it was found that smaller particles have a much 
higher deposition fraction in rodent animal models (Zhang et al., 2008). A later study 
provided supportive results that the deposition patterns of aerosols between 0.5 and 5.0 
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µm (MMAD) showed an increase in both overall and peripheral deposition as the 
particle size decreases using polydispersed particles followed by SPECT/CT imaging 
for analysis (Kuehl et al., 2012). Another report using positron emission tomography 
measured the distribution and transport of ~100 nm polystyrene nanoparticles labeled 
with 64Cu and showed that the inhaled nanoparticles primarily deposited in the lung and 
stayed in the lung steadily for 48 hr (Palko et al., 2010). Combining this data with the 
data from Raabe’s study (Raabe, 1988), the trend of changes of deposition efficiency 
with particle size can be depicted: for particles larger than 5 μm, over 90% of particles 
will deposit in nasal-pharygeal zone, and for particles from 150 nm to 5 μm deposition 
increases as the particle size decreases.  
Factors other than particle size were also studied. An ex vivo fluorescent imaging 
approach using aluminum phthalocyanine tetrasulfonic acid (AIPCS) particles of varied 
sizes was developed to measure the particle distribution inside the lung, and showed 
that the aerosol deposition is clearly linked to lung function (Yi et al., 2012). The 
relationship between drug particle deposition and cancer phenotypes were studied ex 
vivo using MALDI instrumentation in imaging mode. This provided a method to 
measure the mass deposition in the mouse lung, although the original study did not 
deliver the drug via aerosol (Marko-Varga G et al., 2011). Instead of mapping the 
particle distribution patterns, a novel technique of synchrotron phase-contrast X-ray 
imaging (PCXI) was developed to track a single particle down to 5 µm in a live mouse 
trachea (Donnelley et al., 2010). This technique might facilitate the modeling of a single 
particle’s trajectory within the mouse trachea if the resolution could be refined. 
Most of the reports mentioned above focused on developing novel measurement and 
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imaging techniques. Only one focused on the particle generation process (Zhang et al., 
2008). In this dissertation, I made additional efforts and attempted to characterize both 
polydisperse and monodispersed particles for future improvement of particle generation 
methods. 
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Chapter 3 Experimental Methods 
3.1 Animal Experiment 
In this study, a benzo[a]pyrene (B[a]P)-induced female A/J mouse model was used to 
evaluate the inhibitory effects of potential chemopreventive agents. A/J mice are an 
inbred strain ①  of mice that are extremely sensitive to the development of both 
spontaneous and chemically induced lung tumors. The formation of adenocarcinoma in 
the A/J mouse lung involves K-ras (Kirsten rat sarcoma viral oncogene homologue) 
mutations which are detected in 30% of lung adenocarcinomas in humans and are, by 
far, the most common mutations other than p53 (Belinsky et al., 1993; Wang et al., 
2012). B[a]P is a tobacco smoke-related carcinogen that has been proven to induce lung 
tumors in mice. B[a]P-induced tumors bear a point mutation predominately in Codon 12 
with a GC to TA transversion② compared with the random mutation pattern detected in 
spontaneous lung tumors. This point mutation is detected in 40% of human lung tumors 
containing an activated K-ras gene (Belinsky et al., 1993). Thus, B[a]P-induced lung 
tumors share both morphological phenotypes and K-ras genotypes in common with 
corresponding human lung tumors.  
                                                              
① An inbred strain is one that is produced using at least 20 consecutive generations of sister × brother or parent × 
offspring matings, or is traceable to a single ancestral pair in the 20th or subsequent generation (The Jackson 
Laboratory, Bar Harbor, ME, US). Website: http://research.jax.org/grs/type/inbred/index.html 
② A transversion is the replacement of a base of one chemical catetory by a base of the other. Transversion occurs 
when either a pyrimidine is replaced by a purine or a purine is replaced by a pyrimidine (Anthony et al., 2008).  
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The use of animals was approved by Washington University’s Institutional Animal 
Care and Use Committee. Female A/J mice at 6 weeks of age were purchased from 
Jackson Laboratories (Bar Harbor, ME). Animals were housed with wood chip bedding 
in an environmentally-controlled, clean-air room with a 12-hour light-dark cycle at a 
constant temperature and a relative humidity of 50%. Drinking water and diet were 
supplied ad libitum.  
 
Figure  3‐1  Post‐initiation  protocol  in  the mouse mimics  the  exposure‐intervention  timing  in 
former smokers. 
 
To mimic the exposure-invervention timing in former smokers who are supposed to 
take drugs after smoke ceccation, a post-initiation protocol (Figure 3-1) was used in the 
study. To initiate the tumors, in general, the mice were given either a single 
intraperitoneal (i.p.) dose of B[a]P (100 mg/kg body weight) in 0.2 ml tricaprylin or two 
doses of B[a]P by i.p. injection (each at 100 mg/kg body weight, one week apart). Two 
weeks after the last dose of B[a]P, the mice were randomly divided into control and 
treatment groups with 12 mice per group. Theoretically, the larger the sample size, the 
better it can represent the population. However, the number of mice in each group was 
limited by time and cost. Based on empirical experience, 12 mice were used for each 
group, to take into account possible variance among mice and possible mortality during 
treatment. Each treatment group had a counterpart control group. The control groups 
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were treated in exactly the same way as the treatment groups except that the control 
groups receive no drugs during the experiment. Oral B[a]P (by gavage) is also used to 
initiate lung tumorigenesis (Steele and Lubet, 2010). However, oral B[a]P can also 
induce esophageal (Wen and Walle, 2007), forestomach (Gangar et al., 2011), and 
gastric tumorigenesis (Goyal et al., 2010). Primary tumors in organs other than the lung 
can highly complicate data interpretation; thus, i.p. injection of B[a]P is preferred as it 
only induces lung tumorigenesis.  
Three administration methods were used in the study, including aerosol inhalation, 
oral gavage, and diet. For aerosol inhalation, the mice were exposed to aerosols in a 
custom-built nose-only exposure chamber which could hold a maximum of 12 mice at 
the same time (Fu et al., 2009). For dietary administration, the drug was well-mixed 
with AIN-76A purified powder diet (Dyets, Inc., Bethlehem, PA) and 3% sugar in a 
KitchenAid (St. Joseph, MI) mixer for one hour. For gavage administration, the drug 
was evenly dissolved or dispersed in a vehicle. The drug solutions or suspensions were 
fed to the mouse in a dose of 0.01ml per gram body weight. The diet was prepared twice 
per week, and fresh diet in the cages was supplied daily.  
The body weight of the mice was monitored and recorded on the same day every 
week during treatment. At the end of the treatment, mice were euthanized by CO2 
asphyxiation and dissected. Larger lung tumors and specimens of non-tumorous lung 
tissue were flash frozen in liquid nitrogen and stored at -80°C for further analysis. The 
rest of the lungs from each mouse were fixed in Tellyesniczky’s solution (90% ethanol, 
5% glacial acetic acid, and 5% formalin) overnight (Zhang et al., 2000) and then stored 
in 70% ethanol. The fixed lungs were evaluated under a dissecting microscope to obtain 
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a fixed surface tumor count and individual tumor diameters. Individual tumor volumes 
(V) were calculated based on the following formula: V (mm³) = πd³/6 (Wang et al., 
2003), where d is the diameter assuming a spherical tumor. The total tumor volume of 
each mouse was defined as the sum of the volumes of all frozen and fixed individual 
tumors. Tumor load was determined by calculating the mean value of the total tumor 
volume per mouse in each group.  
3.2 Aerosol Procedure 
Drugs were dissolved in a 50:50 solution of dimethylsulfoxide (DMSO) and ethanol. 
The solution was nebulized into droplets by custom-built Collison nebulizers. As shown 
schematically in Figure 3-2, generated aerosols were directed to two tandem diffusion 
scrubbers containing activated granulate charcoals (Sigma-Aldrich, St. Louis, MO) to 
remove the ethanol and DMSO.  
 
Figure 3‐2 Schematic diagram of the aerosol delivery system used in the animal study 
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Then, the resultant dry aerosols were introduced into the nose-only exposure chamber 
from the top inlet. Effluent aerosols were discharged from the outlet at the bottom of the 
chamber and then collected with a high efficiency particulate air filter (HEPA filter; Pall 
Co., Port Washington, NY). A vacuum pump and an orifice were connected to the HEPA 
filter to control the total air flow through the chamber at 2 L/m.  
The major differences between this delivery system and the system used in previous 
work (Fu 2009) are the orifice and vacuum pump at the exit of the exposure chamber. 
The orifice guaranteed a constant flowrate and pressure in the system, thereby 
minimizing the bias caused by flow variations inside the chamber.  
The size distribution of the generated aerosols were measured by a scanning mobility 
particle sizer (SMPS) spectrometer which included an electrostatic classifier (TSI model 
3080), a differential mobility analyzer (DMA, TSI model 3081), and a condensation 
particle counter (CPC, TSI model 3025). The geometric median diameter, mass median 
aerodynamic diameter (MMAD), geometric standard deviation (GSD), and the order of 
magnitude of the particle number were obtained. The mass concentration of the drug 
aerosols inside the chamber was measured with off-line and on-line methods. In the 
off-line method, a gravity method, the drug aerosols were loaded on a piece of 
environmentally balanced filter medium at the exit of the exposure chamber during the 
treatment. The filter medium was then re-balanced and weighed to determine the mass 
of the drug aerosols. The total volume of air was determined by the exposure time and 
the air flow rate. The mass concentration inside the chamber was calculated as follows: 
 aerosol,mg/L filter loading,mg min L/min[C]  = M /(exposure time air flow rate )× , (1) 
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where [C]aerosol is the aerosol mass concentration inside the exposure chamber, mg/L, 
and Mfilter loading is the mass of particles loaded on the filter media, mg. 
The on-line method used the Kanomax piezobalance aerosol mass monitor (Kanomax, 
Japan, Inc.). The two methods provided similar results in a certain concentration range, 
although the off-line gravity method was more accurate for large mass concentrations..  
The mass of inhaled drugs was calculated as follows: 
 inhaled aerosolM  = [C] RMV exposure time× × , (2) 
where RMV is the respiratory minute volume of the mouse. The RMV was determined 
by plethysmography either just prior to or during the exposure. In the present study the 
RMV was empirically determined to be 0.025 mg/min, using Guyton’s formula as 
follows (Guyton, 1947): 
 0.75ml gRMV  = 2.1(body weight ) . (3) 
The dose could be estimated as follows: 
 aerosol,mg/L L/min mininhaled
g g
[C] RMV exposure timeMDose =   
body weight body weight
× × =
.
 (4) 
3.3 Statistical Analyses 
The statistical analyses were done with PSAW® Statistics 18 (IBM, Somers, NY) and 
Microsoft® Excel™ 2007 (Microsoft, Redmond, WA). Tumor multiplicity and tumor 
load were analyzed by a two-sided Student’s t-test. For the combination treatment, 
tumor multiplicity and tumor load were analyzed by a one-way analysis of variance 
(ANOVA) followed by the Tukey’s HSD (honestly significant difference) test for 
multiple comparisons to protect against an inflated alpha level, thereby limiting the risk 
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of a Type I error. 
3.4 Summary of Agents Evaluated in the Dissertation 
Twenty four agents were evaluated alone, including synthetic and natural compounds. 
Thirteen pairs of agents were evaluated in combinations. A simple strategy was 
developed to select agents suitable for aerosol delivery (Figure 3-3). The hypothesis was 
proposed and tested that aerosol inhalation could reduce adverse side effects and might 
potentially increase the efficacy of the agent.  
 
Figure 3‐3 A strategy for selecting agents for aerosol inhalation. 
Eight single agents and one combination of agents (Table 3-1) are discussed in great 
detail in the following chapters.   
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Table  3‐1 Potential  chemopreventive  agents  evaluated using  a  post‐initiation protocol  in  the 
B(a)P‐induced A/J mouse model 
 Agents Administration Concentration Completion Time 
Small 
Molecular 
Inhibitors 
Gefitinib 
Aerosol 5 mg/ml Nov. 2009 
Aerosol 10 mg/ml Sep. 2010 
Aerosol 15 mg/ml Sep. 2010 
Aerosol 15 mg/m Oct. 2012 
Erlotinib Aerosol 5 mg/ml Nov. 2009 
Lapatinib 
Aerosol 50 mg/ml Oct. 2012 
Gavage 100 mg/kg body weight Oct. 2012 
Wortmannin 
Aerosol 2 mg/ml Aug. 2011 
Gavage 1 mg/ml Aug. 2011 
Aerosol 2 mg/ml Oct. 2012 
Natural 
Compounds 
Resveratrol Aerosol 15 mg/ml Nov. 2009 
Protocatechuic 
Acid Aerosol 12 mg/ml Oct. 2012 
Anthocyanins Aerosol 5 mg/ml Oct. 2012 
Caffeine Aerosol 10 mg/ml Oct. 2012 
Combination 
of  
Two Agents 
Budesonide Aerosol 1.125 mg/ml Sep. 2010 
Polyphenon E Diet 0.75 % Sep. 2010 
Budesonide + 
Polyphenon E 
Aerosol + 
Diet 
1.125 mg/ml + 
0.75 % Sep. 2010 
 
Their molecular structures are shown in Figure 3-4. Other agents and combinations 
are discussed in the Appendix. 
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Figure 3‐4 Molecular structures of the evaluated agents (I and J were adopted from Pubchem 
Compound: http://www.ncbi.nlm.nih.gov/pccompound). 
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Chapter 4 Chemopreventive Effects of Small Molecular 
Inhibitors via Inhalation 
Four small molecular inhibitors are discussed in this chapter. Three of them (gefitinib, 
erlotinib, and lapatinib) are synthetic compounds, and the last one (wortmannin) is a 
natural compound. Orally-administered gefitinib, erlotinib, and wortmannin are able to 
inhibit lung tumorigenesis in mice, but their efficacy is accompanied by toxicities which 
are not acceptable for long term chemoprevention. Lapatinib has similar toxicity to 
gefitinib and erlotinib but, currently, has not shown inhibitory effects on lung 
tumorigenesis in animal models or clinical trials. Thus, this chapter tests the hypothesis 
that aerosol delivery of small molecular inhibitors reduces the toxicities of the agents 
without compromising their efficacy.  
4.1 Gefitinib and Erlotinib – EGFR Inhibitors① 
EGFR is a transmembrane tyrosine kinase (TK) type I receptor of the ErbB family 
that plays an important role in processes such as cell growth, proliferation, survival, and 
differentiation. Selective blockade of EGFR via newly developed EGFR tyrosine kinase 
inhibitors (TKIs) has been an effective therapeutic approach specifically in 
non-small-cell lung cancer (NSCLC) (Hida et al., 2009). Gefitinib (IressaTM, ZD1839, 
AstraZeneca Pharmaceuticals, DE) (Figure 3-4 A) is the first orally active inhibitor of 
                                                              
① The manuscript has been prepared and will be submitted to Molecular Carcinogenesis.  
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EGFR (HER1 or ErbB1). EGFR-specific gefitinib blocks the nucleotide-binding pocket 
of ErbB proteins, thereby inhibiting receptor autophosphorylation and blocking 
downstream signal transduction (Muhsin et al.,, 2003; Citri and Yarden, 2006). Gefitinib 
has been approved by the U.S. Food and Drug Administration (FDA) for the treatment 
of patients with the most common form of lung cancer, NSCLC, and it is now approved 
in 36 countries worldwide as a first-, second-, or third-line treatment option for NSCLC 
(Hida et al.,, 2009). The possibility of using gefitinib as a chemopreventive agent has 
also recently been studied using murine animal models (Fujimoto et al., 2005; Yan et al.,, 
2006; Kishino D et al.,, 2008; Ohashi et al.,, 2009, 2010; Keith RL et al.,, 2010). 
Gefitinib administered by oral gavage shows inhibitory effects in murine cancer models.  
Erlotinib (Tarceva®, OSI774, OSI Pharmaceuticals, LLC, Farmingdale, NY) (Figure 
3-4 B) is also an orally available reversible ATP-competitive inhibitor of wild-type 
EGFR TK. The mechanism of erlotinib is similar to that of gefitinib. Erlotinib was 
approved by the U.S. FDA in 2004 for the treatment of patients with locally advanced or 
metastatic NSCLC after failure of at least one previous chemotherapy regimen (Pao and 
Miller, 2005). The results of the clinical trials using erlotinib for the treatment of early 
stage, locally advanced, and metastatic NSCLC were reviewed and summarized 
(Gridelli et al., 2010; Lyer and Bharthuar, 2010). Erlotinib has also been examined for 
lung carcinogenesis chemoprevention (Liby et al., 2008; Zerbe et al., 2008; Dragnev et 
al., 2011). 
Although these two small molecular inhibitors have already shown anti-tumor 
activity in a variety of tumor types, alone and in combination with chemotherapy, side 
effects, especially visible mucocutaneous alterations such as rashes, are frequently seen 
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in gefitinib- and erlotinib-treated patients. Owing to the uniform expression of EGFR, 
its high dependence on pathway activity, and ease of access, the skin has been used as a 
surrogate marker of EGFR signaling as similar effects are expected to occur in tumor 
tissue (Lacouture 2006; Gridelli et al., 2010). For chemoprevention, the side effects 
definitely exert negative influences on quality of life and are not acceptable for 
long-term intervention. Therefore, for both chemoprevention and clinical applications, 
the delivery target of these drugs should be controlled with a promise of an effective 
local level in the lung and a minimum systemic level. Aerosol delivery is, clearly, the 
best administration route in this case. Previous studies showed that tumor growth was 
inhibited with no observable side effects (Yan et al., 2006). Further studies performed in 
this dissertation using the same animal model have demonstrated the feasibility of 
delivering small molecular inhibitors by the inhalation route without visible side effects. 
This study represents an effort to determine the efficacy and safety of 
pulmonary–delivered gefitinib and erlotinib with B[a]P-induced lung tumors in mice. 
4.1.1 Animal Bioassays 
4.1.1.1 Efficacy Assays 
Three sets of bioassays were conducted with an incremental dose of gefitinib, and one 
group of erlotinib was added in the first set to ensure the generality of our results. The 
protocols are illustrated in Figure 4-1, and the groups are presented as described 
in Table 4-1. In the first set, female A/J mice were given one single intraperitoneal (i.p.) 
injection of B[a]P (100 mg/kg body weight) in 0.2 ml of tricaprylin. Two weeks after 
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B[a]P injection, the mice were randomly divided into control and treatment groups and 
subjected to aerosol treatment. The control group received DMSO/EtOH (the solvent of 
gefitinib and erlotinib) via inhalation while the treatment groups were given either 
aerosolized gefitinib (0.8 mg/kg body weight) or erlotinib (0.8 mg/kg body weight). The 
mice were treated once a day, 5 days per week for 20 consecutive weeks. In the second 
set, we tested only gefitinib. All the conditions were the same as the first set, except that 
we increased the dose of gefitinib from 0.8 to 1.6 and 2.5 mg/kg body weight. In the 
third set, we repeated the gefitinib dose of 2.5 mg/kg body weight but increased the 
number of induced tumors by using two doses of B[a]P (each at 100 mg/kg body weight, 
one week apart). The treatment lasted for 19 weeks. In all three sets of the bioassay, all 
the solutions were freshly prepared on the same day they were used. The aerosolized 
drug exposure was conducted using the custom-built nose-only exposure chamber. The 
mice inhaled aerosols for 15 minutes by placing their noses into the cone of each 
sub-compartment. 
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Figure  4‐1  Treatment  protocols  of  gefitinib  and  erlotinib:  A,  B,  and  C,  efficacy  assays  for 
gefitinib and erlotinib, and D, toxicity assay for gefitinib. 
4.1.1.2 Skin toxicity evaluation 
In the toxicity evaluation assay, female A/J mice at 8 weeks of age were randomly 
divided into 2 groups with 5 mice in each group: 1) Aerosol 15 (15 mg/ml solution as 
the feeding fluid for the nebulizer); 2) Gavage 100 (100 mg/kg body weight); 3) Gavage 
200 (200 mg/kg body weight). The mice were either gavaged with a dose of 200 mg/kg 
body weight in 1% Tween 80 solution or exposed to gefitinib aerosols for 15 min. Both 
treatments were given 5 days per week for 10 consecutive weeks (Figure 4-1). Photos 
were taken of each individual mouse for comparison.  
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Table 4‐1 Experimental design for the gefitinib and erlotinib bioassay 
Group  No. of 
mice 
Carcinogen  Treatment  Dose (mg/kg 
body weight)‡
Comments on solution 
preparation 
1‐1  12  B[a]P*  DMSO/EtOH‡ — —
1‐2  12  B[a]P *  Gefitinib 0.8 Powdered gefitinib was 
dissolved in the vehicle at 
5 mg/ml. 
1‐3  12  B[a]P *  Erlotinib 0.8 Powdered erlotinib was 
dissolved in the vehicle at 
5 mg/ml. 
2‐1  12  B[a]P *  DMSO/EtOH — —
2‐2  12  B[a]P *  Gefitinib 1.6 Powdered gefitinib was 
dissolved in the vehicle at 
10 mg/ml. 
2‐3  12  B[a]P *  Gefitinib 2.5 Powdered gefitinib was 
dissolved in the vehicle at 
15 mg/ml. 
3‐1  12  B[a]P †  DMSO/EtOH — —
3‐2  12  B[a]P †  Gefitinib 2.5 Powdered gefitinib was 
dissolved in the vehicle at 
15 mg/ml. 
B(a)P*: one single injection at 100 mg/kg body weight in 0.2 ml tricaprylin. 
B(a)P†: two injections and each at 100 mg/kg body weight in 0.2 ml tricaprylin. The second one 
was given one week after the first one.   
Dose (mg/kg body weight)‡: the dose is estimated using Equation (4).   
DMSO/EtOH‡:  DMSO  and  EtOH  were  mixed  at  50:50  ratio  volumetrically  as  the  vehicle  for 
gefitinib and erlotinib. 
4.1.2 Results 
4.1.2.1 Particle size characterization of the drug aerosols 
We first determined the size distribution of the gefitinib (Figure 4-2 A) and erlotinib 
(Figure 4-2 B) aerosols. Particles generated with a Collison type atomizer are 
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characterized by a poly-disperse distribution as a result of the mechanism. The drug 
particles have a size distribution ranging from 0.02 μm to 0.6 μm with σg (geometric 
standard deviation) of 1.8. The mass median aerodynamic diameter (MMAD) of the 
aerosols ranges from 0.12 μm to 0.2 μm with an ascending mass solution concentration 
from 5 to 15 mg/ml. Over 90% of the particles were smaller than 0.3 μm in diameter 
which is a favorable range for drug delivery in a mouse inhalation study (Raabe et al., 
1977, 1988). Additionally, smaller size particles with a diameter down to 0.1 μm have a 
higher chance of being delivered into peripheral alveoli where adenomas and 
adenocarcinomas commonly occur.  
 
Figure 4‐2 Typical size distribution of aerosols generated with the Collison atomizer measured 
at  the  exit  of  the  exposure  chamber. A,  Gefitinib  aerosols  (15 mg/ml  solution); B,  Erlotinib 
aerosols (5 mg/ml solution) 
 
We also measured the mass concentration of the drugs in the chamber by collecting 
the particles at the exit of the exposure chamber on a piece of filter media. The aerosol 
mass concentrations for 5, 10, and 15 mg/ml solutions were approximately 50, 110, and 
170 μg/L, respectively. The respiratory minute volume (RMV) was estimated to be 
0.025 L/min by Guyton’s formula (Guyton, 1947). Based on the information, we 
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calculated the equivalent dose to be 0.8, 1.6, and 2.5 mg/kg body weight. 
4.1.2.2 Inhibitory effect of aerosolized gefitinib and erlotinib individually on lung 
tumor multiplicity and tumor load 
Reduced body weight and mortality are clear signs of systemic toxicity. Based on 
general observations, treatment with either gefitinib or erlotinib aerosols did not have 
any observed adverse effect. No visible skin alterations were observed throughout the 
experiment. Body weight gain was normal. No mouse died in the treatment groups 
during the experiment. This indicates that the inhalation method was well-tolerated at 
the given doses of gefitinib.  
In the first set of the bioassay, B[a]P induced an average of 5.0 ± 0.63 (n = 12) tumors 
per mouse in the solvent control group. The average tumor load of the control group 
was 0.30 ± 0.07 mm3. Aerosolized gefitinib showed some, although not significant, 
inhibitory effects on tumor multiplicity, while aerosolized erlotinib showed no effects 
on tumor multiplicity. However, both drugs significantly decreased the tumor load. 
Gefitinib decreased the tumor load by 39%, and erlotinib showed an even stronger 
effect with a decrease of 63.8% (P < 0.05).  
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Figure 4‐3  Inhibitory effects of  aerosolized gefitinib and erlotinib. A, Aerosolized gefitinib at 
0.8  mg/kg  body  weight  (5  mg/ml  solution)  after  a  single  B(a)P  injection;  B,  Aerosolized 
erlotinib  at  0.8  mg/kg  body  weight  (5  mg/ml  solution)  after  a  single  B[a]P  injection;  C, 
Gefitinib at 1.6 and 2.5 mg/kg body weight (10 and 15 mg/ml solution, respectively) after one 
B[a]P  injection;  and D,  Aerosolized  gefitinib  at  2.5 mg/kg  body weight  (15 mg/ml  solution) 
after  two B[a]P  injections,  one week  apart.  *P <  .05,  ***P  <  .001,  compared with  the  vehicle 
control group. Inhibition rate percentage is also labelled in the figures presented as #%. 
 
In the second bioassay, only gefitinib was tested with higher doses. The tumor 
incidence was 91.7% and 83.3% for the groups treated with gefitinib at 1.6 and 2.5 
mg/kg body weight, respectively, compared with 100% in the vehicle control groups. 
The incidence was dose-dependent in the mice. B[a]P induced an average of 4.1 ± 0.62 
(n = 12) tumors per mouse in the control group with an average tumor load of 0.78 ± 
0.17 mm3. Again, gefitinib (1.6 and 2.5 mg/kg body weight) showed an insignificant 
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trend to reduce the tumor multiplicity but decreased the tumor load by 46.2% and 56.4% 
(P < 0.05), respectively.  
Table  4‐2  Effects  of  aerosolized  gefitinib  at  varied  doses  (5,  10,  and  15 mg/ml  solution)  on 
tumor incidence, tumor multiplicity, and tumor load. 
 
Dose 
mg/kg 
body 
weight 
Tumor 
incidence 
(%) 
Tumor 
multiplicity 
(mean±SE) 
Inhibition 
(%) 
Tumor load 
(mm3,mean±S
E) 
Inhibition 
(%) 
Assay1 (one dose of B[a]P) 
Control - 100 5.0 ± 0.6 - 0.30 ± 0.07 - 
Erlotinib 0.8 100 4.73 ± 0.3 5 0.11 ± 0.02 63.8* 
Gefitinib 0.8 100 3.1 ± 0.4 38.0 0.18 ± 0.02 39.0 
Assay 2       
Control - 100.0 4.09 ± 0.62 - 0.78 ± 0.17 - 
Gefitinib 1.6 91.7 3.00 ± 0.48 26.7 0.42 ± 0.08 46.2 
Gefitinib 2.5 83.3 2.75 ± 0.57 32.8 0.34 ± 0.09 56.4* 
Assay 3       
Control - 100 16.6 ± 1.10 - 3.65 ± 0.36 - 
Gefitinib 2.5 100 8.17 ±1.49 49.8*** 1.57 ± 0.31 56.9*** 
*: P < 0.05, ***: P < 0.001. The solvent control for the three assays is the same 50% DMSO in 
EtOH. 
 
Since there were fewer tumors in the first and second sets, two B[a]P injections were 
given in the third assay. The incidence rate in this case was 100% for both the control 
group and the gefitinib group. Two doses of B[a]P induced an average of 16.6 ± 1.1 (n = 
12) tumors per mouse with a tumor load of 3.65 ± 0.36 mm3. Gefitinib (2.5 mg/kg body 
weight) inhibited tumor multiplicity by 49.8% (P < 0.001) and the tumor load by 56.9% 
(P < 0.001).  
The results are summarized in Table 4-2 and presented in Figure 4-3. The combined 
results of gefitinib in the first and second assays showed a positive dose-response, and 
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in the three different sets of bioassays, gefitinib showed consistent inhibitory effects on 
the tumor load. 
 
Figure 4‐4 Morphological alterations  in  female A/J mice  treated with gefitinib. A, Alopecia at 
the region near the eyelid with average severity in gavage groups (200 mg/ kg body weight). B, 
No alopecia occurred in the aerosol group (2.5 mg/kg body weight). C, Thinning hair  in mice 
with gefitinib by oral gavage. 
4.1.2.3 Observation of skin toxicity in the mice treated with gefitinib by gavage 
and via inhalation 
We further compared the impact of administration methods on the toxicity of gefitinib. 
We observed changes in each group during the 10-week treatment (Figure 4-4). 
Alopecia at the region near the eyelid occurred in all the mice treated by oral gavage at 
doses of 100 and 200 mg/kg body weight (Figure 4-4 A). No alopecia was observed in 
the aerosol inhalation group (Figure 4-4B). One mouse out of five in the gavage group 
at a dose of 100 mg/kg body weight had thinning hair, while all of the mice in the 
gavage group at a dose of 200 mg/kg body weight had thinning hair at later stages of the 
experiment (Figure 4-4 C). Alternatively, mice in the aerosol groups had a normal 
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appearance. Interestingly, the severity of the alopecia and thinning hair seemed to be 
dose-dependent in those mice in the gavage groups. We also observed abnormal white 
spots on the liver upon gross examination in orally-administered gefitinib groups.  
4.1.2.4 Pharmacokinetics of gefitinib and erlotinib 
Gefitinib and erlotinib were both prepared in a 5 mg/ml 50% DMSO/EtOH solution. 
Mice were exposed to aerosols for 15 min and were sacrificed at designated time points 
after exposure. The time at the end of exposure was marked as time zero. Blood and 
lung samples were obtained at time 0, 10, 20, 30, 45, and 60min, homogenized, 
extracted, and analyzed using HPLC. The following parameters were estimated as 
described earlier (Liao et al., 2004): maximum lung concentration (Cmax); the mean area 
under the lung concentration-time curve (AUC); the area under the first moment curve 
(AUMC∞); the mean resident time (MRT) and the lung half time (t1/2). The results are 
shown in Figure 4-5 and Table 4-3.  
Table  4‐3  Pharmacokinetic  parameters  of  gefitinib  and  erlotinib  for  aerosol  administration 
(Data shown in Mean ± SD).   
Parameter Gefitinib Erlotinib 
Cmax (μg/g) 1.81 ± 0.38 4.59 ± 0.70 
AUC (μg/g·h) 2.37 ± 0.83 2.92 ± 0.52 
AUMC∞(μg/g·h2) 2.14 ± 1.11 2.06 ± 0.23 
MRT∞(h) 0.90 ± 0.52 0.71 ± 0.21 
t1/2(min) 93.3 ± 0.60 28.88 ± 1.31 
 
The maximum concentration was achieved at time zero. The concentration in the lung 
decreased with time (Figure 4-5). The half-life of gefitinib and erlotinib in the lung was 
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about 90 min and 30 min, respectively. For erlotinib, low plasma concentration (0.11 
μg/ml) was detected one hour after exposure, which was one tenth of the lung 
concentration (1.1 μg/g lung tissue). For gefitinib, a similar low plasma concentration 
was detected. The results implied that after aerosol delivery gefitinib and erlotinib 
mainly stayed in the lung for the first hour. 
 
Figure  4‐5  Concentration‐time  curves  of  A,  gefitinib  and  B,  erlotinib  in  the  mouse  lung 
following aerosol inhalation (Mean ± Standard Deviation). 
4.1.3 Discussion 
Tremendous progress in our knowledge of cancer at the cellular and molecular levels 
has been made in the past few decades. This knowledge initiates the rise of a novel class 
of drugs that are useful in targeted anti-cancer therapies. These drugs act on a 
well-defined target or biological pathway that, when activated or inactivated, causes 
regression or destruction of the malignant process (Hamilton et al., 2010). Although, at 
present, only a small set of anti-cancer therapies are administered based on the genetic 
alterations present in individual tumors in clinical practice, more targeted anti-cancer 
agents are being widely investigated in preclinical models and clinical trials. Studies of 
some agents even extend to cancer prevention studies.  
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EGFR (epidermal growth factor receptor) mutations currently represent one of the 
best-studied models as a target for anti-cancer therapies. Gefitinib and erlotinib are 
specific inhibitors of the EGFR kinase which effectively binds to the ATP-binding site 
of EGFR tyrosine kinase and blocks the downstream Ras signal transduction cascade. 
Patients with EGFR-mutant non-small cell lung cancer who are treated with EGFR 
TKIs have the longest survival times. Gefitinib and erlotinib have been studied in vivo 
in limited cases for their chemopreventive effects on lung carcinogenesis. Five reports 
for gefitinib in murine models of lung cancer chemoprevention exist (Fujimoto et al., 
2005; Yan et al., 2006; Ohashi et al., 2008, 2009; Kishino et al., 2009; Keith et al., 2010) 
as well as three other reports for erlotinib on its preventive effects (Liby et al., 2008; 
Zerbe et al., 2008; Dragnev et al., 2011). The studies are summarized in Table 4-4. Most 
of the models achieved positive results. Gefitinib dosages ranged from 5 mg/kg to 250 
mg/kg/day, and erlotinib dosages ranged from 10 mg/kg to 200 mg/kg; however, dosage 
is not the only factor that affects the efficacy. Three reports provided direct evidence 
that gefitinib and erlotinib inhibited the phosphorylation of mouse EGFR in vivo (Zerbe 
et al., 2008; Ohashi et al., 2009; Keith et al., 2010). Although one of them used an 
activating EGFR transgenic mice model (Ohashi et al., 2009) to develop tumors driven 
by EGFR mutations, another one injected EGF into the mice to stimulate EGFR 
autophosphorylation (Keith et al., 2010). However, two others reported a feeble signal 
from phosphorylated EGFR in the collected tumors and uninvolved lung tissue (Yan et 
al., 2006; Kishino et al., 2009). These results from different models indicate that 
gefitinib and erlotinib can partly inhibit carcinogenesis independently of the expression 
level or phosphorylation status of EGFR in the mice, but their efficacy is strengthened 
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dramatically in models with activated EGFR mutations. Moreover, the cancer genome is 
complex and may harbor multiple mutations besides EGFR mutations. In the 
smoking-related lung cancer models, EGFR may not be closely associated with 
tumorigenic signaling. Even in the cancer genome in which EGFR mutations exist, the 
interference between the EGFR TKIs and the cancer genome is mutual. Mutations, 
besides activating EGFR signaling and determining the existence of specific proteins 
and enzymes, may either enhance or cancel the efficacy of EGFR TKIs. Thus, EGFR 
TKIs can only partially inhibit carcinogenesis due to the heterogeneity of mutant cells. 
This is the biological limit for the efficacy of EGFR TKIs.  
In this study, we used a typical smoking-related lung cancer model in which B[a]P 
was the carcinogen. We observed a dose-response efficacy of aerosolized gefitinib 
ranging from 0.8 to 2.5 mg/kg body weight. With a much lower dose compared with 
other reports, we achieved 56.4% and 63.8% inhibition on tumor load by gefitinib and 
erlotinib, respectively, which is comparable with other reported results with higher oral 
doses (See refs in Table 4-4). It is the first time for gefitinib and erlotinib to show 
significant inhibitory effects at a dosage lower than 5 mg/kg body weight in 
smoking-related models. This may be attributed to the locoregional delivery via 
inhalation. Improvement of efficacy can be expected within the biological limit with 
increased dosages. However, 200 mg/kg body weight/day for the mouse is equivalent to 
twice that of 500 mg/day for humans (assuming the body weight of a human is 60 kg) 
(Yan et al., 2006), which is exactly the daily dose of gefitinib used for anti-cancer 
chemotherapy. Thus, although a relatively high dose of 200 mg/kg body weight (p.o.) 
showed striking inhibition on tumors (~90% on tumor load; Yan et al., 2006), lower 
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doses are preferred in the chemoprevention of lung cancer. For higher chemoprevention 
efficacy, except for increasing the dosage, a combination of EGFR TKIs and other 
agents is a promising strategy. There have been several attempts made with a variety of 
drugs such as bexarotene combined with erlotinib (Dragnev et al., 2011) and gefitinib 
combined with prostacyclin synthase overexpression (Keith et al., 2010). Further studies 
are needed in the future.  
Despite the anti-cancer benefits of targeted therapies, their specificity also brings 
about concerns regarding frequently occurring adverse effects, such as skin, vascular, 
cardiac, and gastrointestinal toxic effects, because many of the signaling pathways exist 
not only in premalignant cells but also in normal healthy cells (Keefe and Bateman, 
2012). In cancer treatment therapies, the balance between tumor control and adverse 
effects is usually tipped in favor of anti-cancer effects; however, in chemopreventive 
intervention, adverse effects should be managed, minimized, and avoided if possible. In 
general, chemopreventive agents must be easily tolerated in addition to being effective. 
They must cause no decline in the quality of life of the high-risk, but otherwise normal, 
individuals because people may take them for a prolonged time period. This is the 
toxicity limit for small molecular inhibitors, including gefitinib and erlotinib. Reduced 
body weight (Zerbe et al., 2008), light alopecia (Yan et al., 2006), and hepatotoxicity 
(Zerbe et al., 2008) were observed in mouse models. These symptoms appeared in the 
mice treated with relatively high doses of the agents (≥ 50 mg/kg body weight for 
gefitinib, and ≥ 30 mg/kg body weight for erlotinib, p.o. or i.p. injection). In our study, 
visible alopecia and thinning hair was observed in the A/J mouse treated with gefitinib 
(100 mg/kg body weight p.o.) for 10 weeks. We also found white spots in the mouse 
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liver which was reported in another study of erlotinib (Zerbe et al., 2008). The results 
showed that the adverse side effects of gefitinib were not coincidental.  
To reduce the adverse side effects, one of the strategies is to use lower doses with 
conventional oral and intravenous routes. If the dose of the two inhibitors is lowered to 
5 mg/kg body weight, no toxicities are shown when they are administered by gavage or 
i.p. injection (Zerbe et al., 2008; Kishino et al., 2009). However, with such a low dose, 
the efficacy of the inhibitors cannot be guaranteed unless tumorigenesis is totally driven 
by EGFR mutations (SeeTable 4-4).  
Our strategy was to use a locoregional delivery method instead of systemic 
absorption of the agents. In this study, we showed the efficacy of aerosolized gefitinib 
and erlotinib, and, next, we tried to demonstrate the advantage of aerosol delivery from 
a pharmacokinetic (PK) perspective. The plasma, lung, and liver concentration of 
erlotinib following one single injection of 10 mg/kg erlotinib in male and female A/J 
mice was measured in a chemoprevention study (Zerbe et al., 2008). In that particular 
study, the maximum plasma erlotinib concentration appeared at 0.5 hr in male and 
female mice at 4.5 and 5.5 μg/ml, respectively. The maximum liver erlotinib 
concentration was also observed at 0.5 hr in males and females at 3.6 and 6.0 μg/g, 
respectively. The lung erlotinib concentration was only about half of that in the liver at 
each time point with 1.3 and 1.5 μg/g in males and females, respectively, with 0.5 hr as 
the peak level. In our study, erlotinib was given to female A/J mice via inhalation at a 
dose of 0.8 mg/kg. The maximum lung erlotinib concentration was observed at 0 min at 
4.6 μg/g. At 0.5 hr, the lung concentration of erlotinib dropped to 2.1 μg/g, but was still 
higher than the peak lung level after oral administration. During the first hour, there was 
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no erlotinib detected in the plasma. By directly delivering erlotinib into the lung, we had 
a nearly two-fold higher lung erlotinib concentration with on tenth of the dose compared 
with the reported data. This demonstrates the advantage of aerosol delivery in the case 
of erlotinib. However, in the case of gefitinib, the advantage of aerosol inhalation is not 
as evident as it is in the case of erlotinib. Gefitinib was also aerosolized and given via 
inhalation at a dose of 0.8 mg/kg body weight. The maximum lung gefitinib 
concentration was also observed at 0 min at 1.81 μg/g and decreased with time to 1.0 
μg/g at 1 hr. The blood, lung, and liver gefitinib concentration at 2 hrs after a single oral 
dose of 5 mg/kg body weight [14C]-gefitinib was reported to be 0.71, 8.33, and 13.42 
equivalent μg/g (by converting radioactivity to concentration) in the rat (McKillop et al., 
2004). Although the oral dose was about 5 times higher than the aerosol dose, the lung 
concentration of gefitinib in the orally-dosed rat was also 4.6 times higher than that in 
the aerosol-dosed mouse. The only advantage is that aerosol delivery leads to a much 
lower plasma concentration and avoided gefitinib accumulation in the liver before being 
transported to the lung. The differences in the PK properties between gefitinib and 
erlotinib might be due to the chemical properties of the agents and the measurement 
methods. Therefore, we showed that the inhalation route could deliver more or 
comparable amounts of EGFR TKIs into the lung, which is the target organ in lung 
cancer prevention, at a relatively low dose.  
The last control factor in aerosol delivery is the device and technology limit. There is 
no doubt that particle generation methods and design of delivery systems are very 
important technical points in aerosol delivery studies. Once the efficacy and toxicity 
limit is understood for a certain drug, the next step is to improve the delivery efficiency 
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with controllable particle properties. One of the most important parameters is the 
particle size of the drug. The particle size is the key factor for particle transportation in 
the human body, especially in the pulmonary system and lung. Particles with a larger 
size have a much higher chance of becoming lodged in the oropharynx, nasopharynx, 
and trachea. Particles with smaller sizes have a much higher chance of being effectively 
transported and reaching the lung tissue. Furthermore, in our model, even smaller 
particle sizes are required so that the drug particles can reach the peripheral alveolar 
where adenoma mostly occurs. It is worth noting the differences between the pulmonary 
system in humans and in mice (Table 1-1). Human alveoli are 200-400 μm while mouse 
alveoli are only 39-80 μm. The diameter of the terminal bronchioli that directly 
connects to the alveoli is 0.6 mm for humans but only 0.01 mm for mice (Fox et al., 
2007). In other words, mice have finer structures and, consequently, particles with much 
smaller sizes, down to nanometer size, are required while submicron can go far in the 
human pulmonary system. In this study, particle sizes generated using the Collison 
atomizer range from 20 nm to 0.3 micron which is better for the delivery of aerosolized 
drugs deep into mouse lungs compared with those used in previous studies (Dahl et al., 
2000; Liao et al., 2004). However, for nanoparticles, supplying a large enough amount 
of mass for effectiveness might be a problem. More effort needs to be devoted to the 
design of particle generation and delivery systems so the size and the mass throughput 
requirement can be both controlled and satisfied for the applications.  
In summary, the present study successfully delivered the EGFR TKIs via inhalation 
and demonstrated that aerosolized EGFR TKIs, gefitinib and erlotinib, inhibited 
B[a]P-induced tumorigenesis in an A/J mouse model individually without any 
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observable systemic and cutaneous side effects. Therefore, this preclinical study 
indicated that aerosol delivery can potentially offer significant advantages over oral 
administration against human lung cancer and provides a basis for future clinical 
evaluation. 
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Table 4‐4 Reports on gefitinib and erlotinib for the chemoprevention of lung carcinogenesis 
Agent 
Dosage 
(mg/kg body 
weight) 
Route Mouse strain Carcinogen 
Inhibition on Lung Tumors 
Reference Multiplicity Load 
gefitinib 
200 
gavage  Wild-type B(a)P, 100 mg/kg body 
weight, i.p. single injection 
62.5%***  89.3% ***  
Yan et al., 
2006 
Dominant mutant p53 
mice 
74.6% *** 94.9% *** 
200 
gavage  Female A/J B(a)P, 100 mg/kg body 
weight, i.p. single injection 
59.7% *** 81.4% *** 
gefitinib 
5 gavage Female A/J NNK, 10 mmol, i.p. single 
injection 
27%  N/A Kishino et al., 
2009 50 42% * N/A 
gefitinib 5 
gavage Activating EGFR 
transgenic mouse 
N/A 100% 100% 
Ohashi et al., 
2009 
gefitinib 
50 
i.p. 
injection 
Wild-type FVB/N urethane, 1 mg/kg body 
weight, i.p. single injection 
No significant change No significant change 
Keith et al., 
2010 
PGIS verexpressor 50.6% No significant change 
100 
i.p. 
injection 
Wild-type FVB/N urethane, 1 mg/kg body 
weight, i.p. single injection 
No significant change No significant change 
PGIS verexpressor No significant change No significant change 
erlotinib 10  
i.p. 
injection 
Female A/J urethane, 1 mg/g body 
weight i.p. single injection 
N/A -21% * Zerbe et al., 
2008 Male A/J N/A 51.5% *** 
erlotinib 
100 mg/kg 
diet 
diet 
Female A/J 
Vinyl carbamate, two doses 
(0.32 mg/mouse), 
1 week apart 
18% (14 week); 
22% (20 week) 
52% (14 week) 
36% (20 week) Liby et al., 
2008 200 mg/kg 
diet 
diet 30% *(14 week); 
23% (20 week)  
66% **(14 week)  
57% *(20 week) 
*: P < 0.05, **: P < 0.001; ***: P < 0.0001. N/A: Not available in the references. PGIS: prostaglandin I2 (prostacyclin) synthase. PGIS overexpressors: 
transgenic mice with PGIS overexpression. 
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4.2 Lapatinib - A Dual Inhibitor of EGFR and Her2/Neu 
Similar to gefitinib and erlotinib, lapatinib (GW-572016; GlaxoSmithKline, 
Middlesex, UK) is also a member of the 4-anilinoquinazoline group of tyrosine kinase 
inhibitors (TKIs). Lapatinib may have a therapeutic advantage over gefitinib and 
erlotinib because it is a dual inhibitor of EGFR (ErbB1) and HER2 (ErbB2). Lapatinib 
dytosylate (Tykerb®, GlaxoSmithKline) was approved for the treatment of Her2-positive 
advanced or metastatic breast cancer in 2007 and was further approved for the treatment 
of hormone-positive and her2-positive advanced breast cancer in 2010. The use of 
lapatinib for the treatment of lung cancer is still under clinical investigation. Lapatinib 
induced apoptotic cell death in lung cancer cell line A549 singly (Kurtze et al., 2011; 
Diaz et al., 2010) and in combination with other agents (Olaussen et al., 2009), and 
lapatinib significantly reduced tumor size and angiogenesis in the A549 tumor-bearing 
mice (Diaz et al., 2010). Another report showed that a single treatment with lapatinib 
could induce deaths in K-ras-mutated A549 NSCLC adenocarcinoma cells that are 
likely to be resistant to gefitinib and erlotinib (Kurtze et al., 2011). It is also reported 
that lapatinib alone was effective in two other cell lines, human lung cancer cell line 
H1650 (harboring E746-A750 deletion in exon19 of EGFR) and human lung cancer cell 
line H1781 (harboring G776V,C in-frame insertions in exon 20 of ErbB2 with wild-type 
EGFR), but was ineffective in human lung adenocarcinoma cell line H1975 (carrying 
two missense mutations of EGFR, L858R and T790M in exons 20 and 21 of EGFR) and 
H1975 xenograft in vivo (Suzuki et al., 2009). Instead, the combination of lapatinib and 
cetuximab was able to induce down-regulation of EGFR and apoptotic cell death in 
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H1975 cells and completely inhibited tumor growth in the H1975-bearing xenografts 
(Kim et al., 2008). However, although it has gained great success in the Her2 
overexpression of breast cancer, lapatinib monotherapy had a low response in patients 
with advanced or metastatic NSCLC in a randomized Phase II trial (Ross et al., 2010).  
Despite the disappointing results of the clinical trial, lapatinib is still worth 
investigating for the inhibition of lung cancer based on the success of in vitro studies in 
NSCLC cell lines. Lapatinib has not been studied to test its chemopreventive effects on 
lung carcinogenesis. In this work, lapatinib (obtained from National Cancer Institute) 
was administered both by oral gavage and aerosol administration for its inhibitory 
effects on lung tumorigenesis in a mouse model. This is the first time that lapatinib was 
evaluated in a chemoprevention model. 
 
Figure 4‐6 Lapatinib treatment protocol.   
 
Female A/J mice at 6 weeks of age were given two doses of B[a]P (100 mg/kg body 
weight, one week apart) by i.p. injection in 0.2 ml of tricaprylin. The mice were 
randomly divided into 4 groups with 12 mice per group: 1) Aerosol control group (50% 
DMSO in ethanol); 2) Lapatinib aerosol group (50 mg /ml); 3) Gavage control group 
[the vehicle: 0.5 % hydroxypropylmethylcellulose (w/w) with 0.1% Tween 80 in water]; 
4) Lapatinib gavage group (100 mg/kg body wight). The treatment started two weeks 
after the second B[a]P injection. The aerosol procedure was the same as in the case of 
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gefitinib and erlotinib. The mice were treated once a day, five days a week for 19 
consecutive weeks (Figure 4-6). 
 
Figure 4‐7 Body weight changes of lapatinib‐treated groups compared to their corresponding 
control groups during treatment. Error bar: SE.   
 
The body weight was monitored during the 19-week treatment. There was no 
significant difference between the treatment group and the control group for both the 
aerosol and the gavage administration (Figure 4-7). Two mice died in the gavage control 
group and one died in the gavage lapatinib group. The cause of death is unknown. None 
of the mice died in the aerosol treated groups. There was no visible skin alteration or 
other side effects in the mice during the treatment, although, lapatinib has been 
associated with common toxicities of EGFR inhibitors, such as skin rashes and diarrhea 
(Moy and Goss, 2007).  
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Figure  4‐8  Inhibitory  effects  of  lapatinib  administered  by  A,  oral  gavage  (100  mg/kg  body 
weight) and B, aerosol inhalation (50 mg/ml). *: P < 0.05. Inhibition rate percentage is labeled 
for each case. 
 
The tumor incidence was 100% for all the groups with two B[a]P injections. 
Lapatinib inhibited tumor multiplicity and tumor load by both means of administration, 
p.o. and inhalation (Figure 4-8). The results are summarized in Table 4-5. B[a]P induced 
an average of 13.70 ± 2.06 (n = 10) tumors per mouse in the gavage control group, with 
a tumor load of 4.34 ± 0.75 mm3 per mouse. In the lapatinib-treated group (p.o.), tumor 
multiplicity and tumor load were 8.55 ± 1.49 tumors and 2.50 ± 0.46 mm3 per mouse (n 
= 11), respectively. Lapatinib by oral gavage reduced tumor multiplicity and tumor load 
by 37.6% (P = 0.0537) and 42.4% (P < 0.05), respectively.  
For the aerosol groups, B[a]P induced an average of 16.27 ± 1.15 tumors per mouse 
in the aerosol control group, with a tumor load of 3.65 ± 0.63 mm3 per mouse. In the 
lapatinib-treated group (p.o.), tumor multiplicity and tumor load were 9.83 ± 2.48 
tumors and 2.12 ± 0.55 mm3 per mouse (n = 11), respectively. Lapatinib via inhalation 
inhibited the tumor multiplicity and tumor load by 39.6% (P < 0.05) and 41.7% (P < 
0.05).  
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Table 4‐5 Effects of  lapatinib by oral gavage and aerosol  inhalation on tumor multiplicity and 
tumor load. Tumor multiplicity and tumor load were presented as mean ± SE.  
 
Dose 
Tumor 
multiplicity  
Inhibition 
(%) 
Tumor load 
(mm3) 
Inhibition 
(%) 
Gavage Ctrl - 13.70 ± 2.06  4.34 ± 0.75  
Gavage L 100 mg/kg body weight 8.55 ± 1.49 37.6 2.50 ± 0.46 42.4* 
Aerosol Ctrl - 16.27 ± 1.15  3.65 ± 0.63  
Aerosol L 50 mg/ml 9.83 ± 2.48 39.6* 2.12 ± 0.55 41.7* 
*: P < 0.05. The aerosol solvent control group was given 50% DMSO in EtOH. The gavage 
control group was given 0.5 w.t.% hydroxypropylmethylcellulose (w/w) with 0.1 % Tween 80 in 
water.  
 
In this study, aerosol lapatinib (50 mg/ml) is equivalent to approximately 9 mg/kg 
body weight (estimated using Equation 4), which is much lower than the gavage dose 
(100 mg/kg body weight). The fact that aerosolized lapatinib showed comparable 
inhibitory effects to that of orally-dosed lapatinib at a much higher dose (100 mg/kg 
body weight) indicated that aerosol delivery may have advantages over oral 
administration. Pharmacokinetic data are needed as the next step to interpret the 
efficacy results. It is also important to investigate the mechanism of lapatinib on 
B[a]P-induced tumors. 
4.3 Wortmannin - A PI3K Inhibitor 
The phosphatidylinositol-3-kinase (PI3K) signaling pathway is crucial to many 
aspects of cell growth and survival. It is more frequently targeted by genomic 
aberrations including mutation, amplification, and rearrangement (Hennessy et al., 2005; 
Yap et al., 2008). Several abnormalities in the lung cancer pathways are located on or 
related to the PI3K/AKT (AKT: the human homologue of the viral oncogene v-akt) 
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signaling pathway including deletion mutations in P55γ (isoform of p85, found in lung 
cancer cell line HCC15), mutation and amplification of PI3KCA (up to 50%), 
translocations in the forkhead family (> 50% in alveolar rhabdomyosarcoma), mutations 
in PTEN, alternate splicing deletion AA6-273 in EGFRvIII (40%), activating mutation 
(10%) and amplification (variable) of EGFR, mutations in HER2/neu (10% in lung 
adenocarcinoma), and mutations in Ras (~30%) (Hennessy et al., 2005; Yap et al., 2008). 
Some of the abnormalities are acquired and frequently lead to therapy resistance. Thus, 
the PI3K/AKT pathway is an attractive target for the treatment of lung cancer and 
chemoprevention of lung carcinogenesis. Furthermore, as an activated pathway in 
cancer, it is easier to target than the lost tumor suppressors.  
Wortmannin is a steroidal furanoid toxin originally isolated from the fungus 
Penicillium wortamanni in the 1950s (Brian et al., 1957). Later in 1993, it was 
discovered that wortmannin could potently, durably, and irreversibly inhibit 
phosphoinositide 3-kinase (PI3Ks) by covalent inactivation of the enzyme (reviewed by 
Knight 2010; Liu et al., 2012). Wortmannin has been shown to effectively inhibit the 
growth of human NSCLC in vitro and in vivo (Boehle et al., 2002; Hemstrom et al., 
2006). It also enhanced the sensitivity of NSCLC cells to ionizing radiation by 
inhibiting PI3K (Zhang et al., 2010). However, it is restricted to preclinical studies as a 
tool because of its liver toxicity, low stability, and poor pharmacologic properties. 
Wortmannin is one example of the many abandoned drugs that encounter toxicity or 
delivery problems during the translation from preclinical to clinical studies. To 
overcome the disadvantages of wortmannin, two strategies have been proposed and 
conducted. One is modifying the molecular structure of wortmannin to produce PX-866 
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(Ihle et al., 2004), and the other is binding wortmannin to water-soluble polymers to 
form conjugates (Varticovski et al., 2001; Gu et al., 2006). A recent report improved the 
polymer-conjugate method by altering the chain-structure of the conjugate to the 
core-shell structure and finalizing the conjugates into the nanoparticle form (Karve et al., 
2012) for better solubility and lower toxicity. The same approaches can be applied to 
other drugs with similar disadvantages.  
In this study, a different strategy was evaluated for the delivery of wortmannin into 
the lung. Wortmannin was nebulized into nanoparticles and directly delivered into the 
lung via inhalation, avoiding the potential systemic delivery barrier and toxicity. The 
inhibitory effects of wortmannin on lung tumorigenesis were compared between oral 
administration and inhalation administration in a mouse model.  
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Figure 4‐9 Wortmannin treatment protocols. A, Tumors were  induced by one B[a]P injection. 
For the oral gavage groups, the mice were treated once a day, five days per week. A‐I, a dose of 
1.4 mg/kg body weight was given to the mice for two weeks until a severe decrease in the body 
weight was observed; A‐II, all treatment was suspended for four days including weekends; A‐III, 
the oral dose was  reduced  to 1.0 mg/kg body weight until  the end of  the  treatment.  For  the 
aerosol group, the solution was 2 mg/kg body weight. The mice were treated with aerosols for 
10 min a day,  five days per week  for 20 consecutive weeks. B, Tumors were  induced by  two 
doses  of  B[a]P,  one week  apart.  Only  aerosolized wortmannin was  evaluated  using  2 mg/ml 
solutions. The mice received aerosol  treatment  five days per week  for 19 consecutive weeks. 
B‐I, the mice were subjected to wortmannin aerosols for 10 min per day for 5 weeks. B‐II, the 
exposure duration was reduced to 5 min per day for the rest of the treatment. 
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Figure  4‐10  Body  weight  changes  of  wortmannin‐treated  groups  compared  to  the  control 
groups  during  treatment.  The  body  weight  was  monitored  as  an  indicator  of  the  systemic 
toxicity of the drug. A and B refer to protocols in Figure 4‐9. Error bar: SE.   
 
Two bioassays were designed. In the first assay, female A/J mice at 6 weeks of age 
were given a single intraperitoneal (i.p.) injection of B[a]P (100 mg/kg body weight) in 
0.2 ml of tricaprylin. Two weeks after the B[a]P injection, the mice were randomly 
divided into 4 groups with 12 mice per group: 1) Aerosol control group (50% DMSO in 
ethanol); 2) Aerosol wortmannin group (2 mg wortmannin/ml vehicle); 3) Gavage 
vehicle control group (0.4 % DMSO in saline); 4) Gavage wortmannin group (1.4 mg 
wortmannin / kg body weight for the first 2 weeks, and after that, adjusted to 1.0 mg / 
kg body weight). Two weeks after the i.p. injection, the mice were treated once a day, 
five days a week for 20 consecutive weeks (Figure 4-10). The solutions for aerosol 
groups were prepared weekly and stored at -20°C in aliquot. The solutions for gavage 
were freshly prepared on the same day of use. The inhalation exposures were conducted 
using a custom-built nose-only exposure chamber. The mice were exposed to aerosol for 
10 minutes by placing their noses into the cone of each sub-compartment. The body 
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weight of the mice was recorded on the same weekday every week during treatment. 
For the gavage groups, the amount of administered solutions was adjusted based on 
body weight. 
In the first bioassay, aerosol treatment did not cause mortality during the 22 weeks of 
study. Aerosolized wortmannin (2 mg/ml solution, Wort-A I) caused little adverse 
effects on the body weight of mice (Figure 4-10 C). At the end of 22-weeks, the mean 
body weight of the mice in the Wort-A I group was 23.2 ± 0.58 g, compared with 21.8 ± 
0.53 g in its corresponding solvent control group. There was no significant difference in 
the body weight between these two groups. For the gavage wortmannin group (Wort-G), 
a dose of 1.4 mg/kg body weight was given in the first two weeks until a dramatic 
decrease in the mean body weight as well as the deaths of two mice were observed. 
Medication administration was then modified so that the mice could recover their body 
weight for up to four days (including weekends). Additionally, the dose was reduced to 
1.0 mg/kg body weight for the remainder of the experiment. Even with the lower dose, 
the body weight gain in the gavage wortmannin group was much lower than the gavage 
control group (Figure 4-10 C). At the end of the experiment, the mean body weight in 
Wort-G group was 19.74 ± 0.44 g, which was significantly lower (P < 0.001) than the 
average body weight of 23.30± 0.61 g for the control group, which was about 3.50 g 
less on average.  
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Figure 4‐11 Inhibitory effects of wortmannin on B[a]P‐induced lung tumors in the A/J mouse. 
A, and B,  tumors were  induced by one B[a]P  injection. C,  tumors were  induced by two B(a)P 
injections. A, wortmannin p.o.; B, C, wortmannin via inhalation. *, P < 0.05; **, P < 0.001; ***, P 
< 0.0001. Inhibition rate percentage is labeled on top of the bar.   
 
In the first assay, both aerosol and oral administered wortmannin were evaluated. In 
spite of the side effect causing body weight loss, orally dosed wortmannin showed a 
significant inhibitory effect on B[a]P induced tumors. The incidence rate of tumors in 
the Wort-G group was 50% (n = 10) while all the mice in the gavage control group (n = 
12) had tumors by the end of the experiment (Table 4-6). As shown in Figure 4-11, 
wortmannin p.o. decreased tumor multiplicity by 85.5% (0.70 ± 0.26 tumors, n = 10, P 
< 0.001) and tumor load by 78.0% (0.15 ± 0.14 mm3, n = 10, P < 0.05) compared with 
4.83 ± 0.82 tumors and 0.70 ± 0.19 mm3 in the gavage control group (n = 12). 
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Interestingly, wortmannin seemed to strikingly reduce the tumor multiplicity, with only 
a few larger tumors. 
Table 4‐6 Effects of wortmannin by oral gavage and aerosol  inhalation on  tumor multiplicity 
and tumor load. Tumor multiplicity and tumor load are presented as mean ± SE.  
 Dose Incidence 
Tumor 
multiplicity 
Inhibition 
Tumor load 
(mm3) 
Inhibition 
(%) 
GC - 100% 4.83 ± 0.81  0.70 ± 0.18 - 
Wort-G 
1.0 mg/kg 
B.W.a 
50% 0.70 ± 0.26 85.5%** 0.15 ± 0.14 77.9%* 
AC 1 - 100% 3.73 ± 0.85  0.77 ± 0.22 - 
Wort-A 1 2 mg/mlb 91.7% 1.83 ± 0.32 50.8%* 0.16 ± 0.05 79.7%* 
AC 2 - 100 17.27 ±1.15  3.65 ± 0.36 - 
Wort-A 2 2 mg/mlc 91.7% 5.42 ± 2.12 66.7%** 0.72 ± 0.19 80.4%*** 
*: P < 0.05, **: P < 0.001; ***: P < 0.0001. The aerosol solvent control group was given 50% 
DMSO in EtOH. The gavage control group was given 0.4 % DMSO in saline. a: 1.4 mg/kg body 
weight for the first 2 weeks, 1.0 mg/kg body weight from the 5th week to the end of the protocol. 
b: Mice were subjected to aerosol treatment for 10 min. c: The exposure duration was 10 min for 
the first 5-week treatment, and then was reduced to 5 min until the end of the protocol.  
 
The tumor incidence rate in the aerosol control group was 100%, while the incidence 
rate in the Wort-A group was 91.6%. No visible surface tumors were observed in one 
out of twelve mice (Table 4-6). Aerosolized wortmannin showed inhibitory effects on 
lung tumor multiplicity and tumor load significantly (Figure 4-11). Aerosolized 
wortmannin (2 mg/ml solution) decreased tumor multiplicity by 50.8% (1.83 ± 0.32, n = 
12, P < 0.05) and tumor load by 79.7% (0.16 ± 0.05 mm3, n = 12, P < 0.05) compared 
with the solvent control group in which, on average, tumor multiplicity and tumor load 
were 3.73 ± 0.85 and 0.77 ± 0.22 mm3 (n = 12), respectively. All of the observed tumors 
in the aerosol wortmannin group were smaller than 1.0 mm in diameter.  
In the second bioassay, only aerosolized wortmannin was examined. Two B[a]P 
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injections induced many more tumors than one single B[a]P injection (Figure 4-11). The 
incidence of tumors in the control group and the wortmannin treatment group were 100% 
and 91.7%, respectively. The aerosol control group had 16.27 ±1.15 tumors (n = 12) per 
mouse on average, and the tumor load was 5.42 ± 2.12 mm3 per mouse. Aerosolized 
wortmannin significantly reduced the tumor multiplicity and tumor load by 66.7% (P < 
0.001) and 80.4% (P < 0.0001), respectively. The results of the second bioassay 
confirmed the conclusion from the first bioassay. However, the body weight in the 
wortmannin treatment group was 7.3% less than that of the control group (P < 0.05). 
Although the body weight difference was within 10% compared to the control group, it 
is unknown wheter the decrease in the body weight gain was contributive to the 
inhibition of the tumors or not.  
Pharmacokinetic data are necessary to interpret the inhibitory effects of wortmannin 
and the differences in toxicities when it is administered via oral gavage and aerosol 
inhalation. Since there was still a toxicity concern when using aerosol delivery, as 
shown in the second bioassay, a safer approach might be the combination of polymer 
coating and aerosol delivery. 
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Chapter 5 Chemopreventive Effects of Natural Compounds 
via Inhalation 
In this chapter, four plant-based natural compounds, resveratrol, caffeine, 
anthocyanins, and protocatechuic acid, are evaluated. These compounds exist 
ubiquitously in nature and are found in our daily diet. Intake of an appropriate amount 
of these compounds is generally non-toxic and beneficial to human health. All of the 
four compounds have shown cancer prevention effects in vitro and in vivo. However, 
their lung cancer prevention effect is controversial. It is suspected that their anti-cancer 
effect is related to their metabolism and pharmacokinetics. Thus, the hypothesis to be 
tested in this chapter is that aerosol delivery reduces exposure of other organs to the test 
agent and may increase the locoregional quantity of the compound in the lung.  
5.1 Resveratrol① 
Resveratrol, trans-3,5,4’-trihydroxy-trans-stilbene (Figure 3-4 E), is a natural 
phytoalexin produced by a variety of plants (Whyte et al., 2007). It is particularly 
abundant in the skin of grapes and is, consequently, an ample component of red wine 
and grape juice. It is synthesized de novo by plants in response to stress, injury, fungal 
infection, ozone exposure, or UV irradiation (Amri et al., 2012; Neves et al., 2012). The 
compound was first isolated in 1940 from the roots of hellebore and then from the roots 
                                                              
① The manuscript is under preparation. The evaluation of resveratrol in VC-induced mice was done by Dr. Huijing 
Fu as part of her PhD work.  
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of Polygonum Cuspidatum, a plant used traditionally in Chinese and Japanese 
medicines. Since the 1990’s, there have been many studies that show the multiple 
beneficial health effects of resveratrol, including cancer prevention (Athar et al., 2007; 
Bishayee 2009), cardioprotection (Penumathsa et al., 2009; Wu et al., 2011), and 
prolongation of lifespan (Das et al., 2010; Lekli et al., 2010) in several species. There 
are many in vitro and in vivo studies providing a rationale to support the use of 
resveratrol in human cancer chemoprevention. The chemopreventive properties of 
resveratrol are attributed to its anti-oxidant, anti-inflammatory effects, and its ability to 
modulate multiple genes and enzymes (Whyte et al., 2007; Bishayee 2009; Bae et al., 
2011).  
Oral administration is the most convenient way to take resveratrol since the 
compound exists in wine and other foods. Nevertheless, bioavailability of resveratrol is 
always a concern. Because resveratrol has a short half-life in vivo due to its rapid 
metabolism and elimination, its application as a chemopreventive or a chemotherapeutic 
agent is limited. The most convincing in vivo evidence of the anti-tumor activity of 
resveratrol exists in the tumors it can contact directly. Topical application of resveratrol 
against non-melanoma skin cancer in the rodent model always shows consistent 
inhibitory effects (Athar 2007; Bishayee 2009). Moreover, oral administration of 
resveratrol significantly inhibits gastric and colorectal carcinogenesis in various rodent 
models (Bishayee 2009; Sengottuvelan et al., 2009). However, oral administration of 
resveratrol shows conflicting results or minor efficacy in other organs, such as the lung, 
despite the positive results from in vitro studies. This controversy remains unsolved, and 
the variation in efficacy of results is often attributed to the low bioavailability of 
Chapter 5 Chemopreventive Effects of Natural Compounds via inhalation 
78 
resveratrol. Strategies to improve the bioavailability of resveratrol include examining 
alternative delivery routes, developing innovative formulations, and modulating the 
metabolism of resveratrol (Bishayee 2009; Amri et al., 2012).  
In this study, we addressed the inhibitory effects of resveratrol (Fisher Scientific 
Service, Thermo Fisher Scientific Inc., US) on lung carcinogenesis in A/J mice. We 
used inhalation delivery to increase the concentration of free resveratrol in the lung. The 
results were encouraging. Furthermore, we compared the pharmacokinetic profiles of 
the oral and inhalation routes. The results suggest that aerosol administration of 
resveratrol has significant advantages in comparison to oral administration, as shown in 
lung and plasma concentration-time curves. 
5.1.1 Experimental Methods 
5.1.1.1 Animal Bioassay 
We first examined the effect of aerosolized resveratrol on lung tumors. 
Chemoprevention studies were performed using vinyl carbamate (VC)-induced and 
benzo[a]pyrene-induced (B[a]P) female A/J mouse models. Then, we conducted a 
pharmacokinetic study to determine the plasma and lung levels of resveratrol following 
oral and inhalation delivery to a Swiss mouse model.  
In the chemoprevention study, we used the post-initiation protocol schematized 
in Figure 5-1 in carcinogen-induced A/J mouse models.  
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Figure 5‐1 Resveratrol treatment protocol. The aerosol treatment started two weeks after the 
1st injection of vinyl carbamate or the single injection of benzo[a]pyrene.   
 
At the age of eight weeks, to initiate tumor growth, carcinogen was administered to 
mice. The B[a]P group received one single intraperitoneal (i.p.) injection of B[a]P (100 
mg/kg body weight) in 0.2 ml of tricaprylin. The VC group received two i.p. injections 
of VC (0.32 mg per injection in 0.2 ml sterile saline without pH adjustment) once a 
week for two consecutive weeks. The mice then were randomly divided into control and 
treatment groups with 12 mice per group. To dissolve resveratrol, 50% DMSO in 
ethanol was used as the vehicle. The treatment group was given resveratrol, while the 
corresponding control group was given vehicle only. To eliminate bias, all the other 
procedures were the same for the control and treatment groups. Specifically, we had five 
groups: 1) VC-Control group; 2) VC-Res7.5 (7.5 mg/ml Resveratrol in vehicle); 3) 
VC-Res15 (15 mg/ml resveratrol in vehicle); 4) BP-control group; 5) BP-Res15 (15 
mg/ml resveratrol in vehicle). All the solutions were prepared fresh daily. The body 
weight of the mice was recorded on the same weekday every week during the treatment.  
Two weeks after the first i.p. injection of either carcinogen, the treatment regimen 
began. The mice were treated with aerosolized resveratrol for 15 min per day, five days 
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a week, for 18 or 20 consecutive weeks. The mice in the VC groups were sacrificed by 
CO2 asphyxiation after 18 weeks of treatment, and the mice in the B[a]P groups were 
euthanized by CO2 asphyxiation after 20 weeks of treatment. 
In the pharmacokinetics study, we used female NIH Swiss mice. For the aerosol 
administration, mice were exposed to the aerosol cloud for 15 min using a solution of 
15 mg/ml resveratrol in the vehicle. Following exposure, the animals were sacrificed by 
cervical dislocation at 1 of the 7 designated time points (0, 5, 10, 15, 30, 60, and 120 
min) in groups of three, where the end of the exposure marked zero time. Blood was 
obtained from the retro-orbital sinus and was collected into EDTA-pretreated eppendorf 
tubes. The tubes were centrifuged and the plasma removed and stored at -80 oC until 
assayed. The lung was severed at the carina, the esophagus and trachea were removed, 
and the lung was collected in a cryogenic vial, snap-frozen in liquid nitrogen, and later 
stored at -80 oC until assayed.  
For the oral administration, groups of three animals received resveratrol by gavage at 
a dose of 75 mg/kg body weight in 0.2 ml solution (equivalent to 500 ppm in diet if a 
single mouse consumed 3 grams of food per day). The animals were sacrificed, and the 
plasma and lung samples were collected and processed as described above.  
5.1.1.2 Tissue Assay Method 
The lung tissue was weighed, frozen in liquid nitrogen, and crushed with a pre-cooled 
tissue pulverizer. The crushed tissue was collected in an eppendorf tube with 200 μl of 
distilled water and vortexed to form a uniform homogenate. After the addition of 500 μl 
of acetonitrile, the samples were vortexed for two minutes and centrifuged at 13,200 
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rpm for 15 min at 4 oC to precipitate the proteins. The supernatant was removed by a 
syringe, through a 0.2 μm Nylon syringe filter (Whatman GD/X, 13mm, and disposable), 
dried using nitrogen, and then reconstituted with 200 μl of methanol. The blood plasma 
was processed in the same way as the lung tissue homogenate. The mobile phase 
consisted of 50 mM ammonium acetate (pH = 2.2) and acetonitrile, with a ratio of 70:30. 
The flow rate of the mobile phase was 1 ml/min. The detection wavelength was 308 nm.  
Resveratrol was quantified by HPLC. The HP 1100 series HPLC system that was 
used for separation consisted of an autosampler, a quaternary pump, a thermostatted 
column compartment, and a UV detector (Agilent Tech, Santa Clara, CA). An Agilent 
Zorbax SB-C18 (4.6 × 125 mm, 5.0 μm) column was used.   
5.1.1.3 MTT Proliferation Method 
Inhibitory effects on the growth and viability of cells were determined using the 
tetrazolium dye (MTT; 3[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) 
assay described in Horiuchi et al., 1988. An MTT kit was purchased from Promega 
Corporation (Madison, WI, U.S.). Human lung cancer cell line A549 was cultured in 
100 μl medium, plated in 96-microwell plates with 5, 000 cells / well, and incubated for 
24 hr. Resveratrol at 15 μM and 30 μM was tested. The cells were incubated further for 
48 hr with the drug. 100 μl of thawed PMS (phenazine methosulphate) solution was 
added to 2.0 ml thawed MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) 
-2-(4-sulfophenyl)-2-tetrazolium) solution, and was immediately well mixed. The 
MTS/PMS solution (20 μl) was pipeted to each well of a 96-well assay containing 100 
μl of culture medium. After incubation for 4 hr at 37 oC in humidified 5% CO2, the 
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optical density (OD) of the wells was determined using an ELISA microplate reader at 
an absorbance wavelength of 490 nm. Each plate contained “blank” background control 
wells holding an appropriate volume of media but no cells. All experiments were 
performed three times. The control cells were grown under the same conditions without 
the addition of resveratrol. Cell survival (% of control) was calculated relative to 
untreated control cells. We also validated the results using a second human lung cancer 
cell line, H1129, employing the same method as described above.  
5.1.2 Results 
5.1.2.1 Inhibitory effects of aerosol resveratrol on VC- and B[a]P-induced lung 
carcinogenesis in female A/J mice 
The body weight of the mice was recorded weekly. In general, for both VC- and 
B[a]P-induced mice, there was no significant difference between the control groups and 
the resveratrol groups. Aerosolized resveratrol was well-tolerated at the given dose and 
showed no adverse systemic effect.  
VC induced more tumors with a larger tumor load than B[a]P did. In VC-induced 
groups, aerosolized resveratrol showed no inhibitory effect on tumor multiplicity but did 
show a significant effect on tumor load (Figure 5-2 A). The decrease in tumor load was 
26.3 % (P < 0.05) for VC-Res7.5 and 36.0 % (P < 0.01) for VC-Resv15. Increased 
inhibition was achieved with a higher dose. In the B[a]P-induced group, resveratrol (15 
mg/ml resveratrol solution) showed significant inhibitory effects on both tumor 
multiplicity and tumor load (Figure 5-2 B). The average tumor multiplicity and tumor 
load were decreased by 37.1% (P < 0.05) and 72.0% (P < 0.01), respectively. 
Chapter 5 Chemopreventive Effects of Natural Compounds via inhalation 
83 
 
Figure 5‐2 Inhibitory effects of resveratrol on VC‐ or B[a]P‐induced tumors in A/J mice. A, vinyl 
carbamate‐induced lung tumorigenesis; B, benzo[a]pyrene‐induced lung tumorigenesis. 
5.1.2.2 Effect of resveratrol on human non-small cell cancer cell line A549 in the 
MTT assay 
The inhibitory effect on tumor cells as a function of resveratrol concentration was 
determined using human lung cancer cell line A549, and this was repeated in three 
experiments. For A549 cells incubated for 48 hrs, 15 μM resveratrol achieved around 10% 
reduction of the formazan product, while 30 μM resveratrol resulted in about a 30% 
reduction (Figure 5-3). Resveratrol showed an inhibitory effect on the proliferation of 
lung cancer cell line A549, and the effect was dose-responsive. We also validated the 
results using a second human lung cancer cell line, H1299. The maximum inhibition 
rate occurred at 24 hr. 
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Figure 5‐3 Inhibitory effects of resveratrol in the cell proliferation of human non‐small cell lung 
cancer cell line A549. Inhibition rate percentage is shown on top of each bar. 
5.1.2.3 Lung distribution of resveratrol following oral and inhalation delivery 
The exposure chamber provided an aerosol cloud of dry particles of resveratrol at a 
concentration of 0.169 ± 0.014 mg/L for 15 mg/ml resveratrol solution. This is 
equivalent to 2.5 mg/kg body weight. The size of the aerosols ranged from 0.02 μm to 
0.5 μm. The MMAD was 0.2 μm and the GSD was 1.8.  
In Figure 5-4 B, the concentrations in the lung and plasma are given as a function of 
time following aerosol treatment. For the lung, the concentration immediately following 
exposure, which was taken as time 0, was 8.9 nmol / g lung. This concentration fell 
slowly with time, so that even at 2 hours, the concentration was 0.45 nmol / g. The 
plasma level following inhalation delivery, at time 0, had a concentration of 0.89 nmol / 
mL, which was about one tenth of the lung concentration. This was the highest 
concentration observed. With time, the plasma concentration decreased. At 2 hours, the 
concentration was 0.1 nmol/L, which was low but detectable. 
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Figure 5‐4 Blood and lung concentrations of resveratrol  in mice dosed by gavage (A) and via 
inhalation (B), respectively. 
 
Figure 5-4 A shows the lung and plasma levels following oral administration. For the 
lung, the peak concentration of 1.43 nmol/g appeared at 5 min after treatment. Within 
10 min, the concentration fell rapidly to about 0.21 nmol/g. At one hour, the level of 
resveratrol was not measurable. For the blood, the peak concentration of 3.78 nmol / mL 
also appeared at 5 min, which was about 2.5 times higher than the peak lung 
concentration. It also fell rapidly within 10 min, to a level of 0.16 nmol / mL. 
Table  5‐1  The  pharmacokinetic  parameters  calculated  for  gavage  dosing  (75  mg/kg  body 
weight) and aerosol inhalation (equivalent to 2.5 mg/kg body weight).   
 Gavage Aerosol 
 Plasma Lung Plasma Lung 
AUC, nM·min 40 18.6 9.9 284.0 
AUClung/AUCplasma 0.465  28.7  
AUMC∞, nM·min2 228.2 69 302.2 9786.9 
MRT, min 12.3 17.3 30.6 34.5 
t1/2, min 2.2   33.8 
Cmax, nM/g or nM/ml 3.78 1.43 0.89 8.2 
tmax, min 5 5 0 5 
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Other parameters estimated from the concentration-time curve are given in Table 5-1. 
The AUClung following aerosol delivery (at a dose of 2.5 mg/kg body weight) was 284 
nM·min, whereas the corresponding parameter following oral dosing (at a dose of 75 
mg/kg body weight) was only 19 nM·min. Thus, the AUClung was 14 times greater when 
the drug was administered by aerosol, even with a lower dose. Conversely, the 
AUCplasma following aerosol delivery was 10 nM·min, which was lower than that of 40 
nM·min following gavage.  
For aerosol delivery, the (AUClung/AUCplasma)inhalation value was 28.7. However, after 
gavage, the (AUClung/AUCplasma)gavage was only 0.47. Thus, the therapeutic advantage of 
these two delivery modalities can be estimated as follows: 
 ( ) ( )lung plasma lung plasmainhalation gavageAUC / AUC /  AUC / AUC 28.7 / 0.47  61= =  (5) 
 (AUClung/AUCplasma) is like a partition coefficient which describes the distribution of 
a substance in the lung and the blood in vivo. When (AUClung/AUCplasma) is greater than 
1, it means that more of the test agent is delivered to the lung than to the blood. The 
ratio obtained using Equation (5) is a measure of the difference in the partition 
coefficients of two delivery approaches, inhalation and oral gavage. When the ratio is 
greater than 1, it means that aerosol inhalation can deliver more resveratrol to the lung 
than oral gavage. Thus, the greater the ratio, the larger is the advantage of aerosol 
inhalation. In the case of resveratrol, it is clear that aerosol delivery has a significant 
advantage over the oral route. 
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5.1.3 Discussion 
In this study, resveratrol delivered by inhalation was evaluated as a chemopreventive 
agent in a VC- and a B[a]P-induced A/J mouse model. The results of our study show 
that resveratrol delivered by inhalation is effective in reducing the load of VC-induced 
tumors and in reducing both the number and the load of B[a]P-induced lung tumors in 
A/J mice. As a supplement, we also evaluated the effect of resveratrol on the 
proliferation of cancer cells in vitro using an MTT assay. Consistent inhibition rates 
were obtained in repeated experiments.  
Positive results are not rare in most studies of resveratrol as a cancer preventive agent. 
However, where lung cancer is concerned, negative results have predominated in the in 
vivo studies. Hecht et al (1999) and Berge et al (2004) both failed to show an effect of 
dietary resveratrol on lung carcinogenesis in vivo. Hecht et al (1999) did not explain the 
reason. The results described by Berge et al (2004) resembled the findings of Hecht et al 
(1999); however, they suspected that the bioavailability of resveratrol might be the key. 
In their studies, no resveratrol or its conjugates were found in the tissues of animals 
receiving the compound in the diet in their studies. Interestingly, in some other studies, 
intact resveratrol has been detected in mouse lung tissue after a single intragastric 
delivery (Vitrac et al., 2003; Sale et al., 2004). Other studies argued that it is the rapid 
clearance in the mouse tissue rather than the poor bioavailability that adversely affects 
the prevalence of resveratrol (Asensi et al., 2002; Yu et al., 2002). In this study, we also 
observed measurable levels of resveratrol in mouse lung tissue after a single dose by 
gavage. Thus, the negative results in previous in vivo studies can possibly be attributed 
to the hypothesis that resveratrol given in the diet may not have reached the lung “in 
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sufficient concentrations or biological active form” (Berge et al., 2004) due to its low 
bioavailability and poor metabolism (if the measurement method that was used was 
sensitive enough). 
To solve the delivery problem, three strategies are often considered: looking for a 
substitute for resveratrol, such as DMU (trans 3,4,5,4’-tereamethoxystilbene) ( Sale et 
al., 2004) which has a better metabolism profile; exploring proper formulation solutions 
to overcome the delivery limitation; and trying other administration routes, as we did in 
our study. Inhalation is not a novel route for lung and respiratory diseases; however, it is 
novel for resveratrol. In this study, we demonstrated that resveratrol has inhibitory 
effects on lung carcinogenesis in vivo and further interpreted the results from the 
perspective of pharmacokinetics. Plasma and lung levels of resveratrol were determined 
in mice following oral and inhalation delivery. The results showed that inhalation 
delivery of resveratrol resulted in obviously, significantly higher levels in the lung when 
compared with oral dosing. Analysis of the concentration as a function of time suggests 
that a pharmacokinetic advantage of 61 is obtained in the mouse between inhalation and 
oral routes. Further studies on aerosol delivery of resveratrol are merited for verification 
and improvement. Ultimately, resveratrol can certainly be considered as a potential 
chemopreventive agent for lung carcinogenesis. 
5.2 Caffeine 
Studies on caffeine’s antitumor effects date back to the 1970s (Kakunaga, 1975; 
Nomura, 1976; Nomura, 1977; Theiss and Shimkin, 1978). In the last 20 years, caffeine 
has always been studied together with tea or tea polyphenols, such as EGCG, to 
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elucidate the mechanisms of the cancer chemopreventive effects of the tea (reviewed by 
Yang et al., 2011). Caffeine itself has been studied extensively by Conney et al. for its 
chemopreventive effects on UVB-induced skin carcinogenesis in mouse models 
(reviewed by Conney et al., 2007, 2008, 2013). The study was further extended to 
caffeine analogues (Rogozin et al., 2008) and caffeine sodium benzoate (Lu et al., 2007), 
which might potentially inhibit UVB-induced skin tumorigenesis. Caffeine was also 
shown to prevent carcinogen-induced lung tumorigenesis in mouse models. Urethane 
and NNK, two chemicals existing in tobacco smoke, are two commonly used 
carcinogens in the evaluation of caffeine. In earlier studies, varied schedules and doses 
of urethane and caffeine were tested, which lead to dissimilar conclusions on its 
inhibitory effects on lung adenoma (Theiss and Shimkin, 1978; Armuth V and 
Berenblum I, 1981). Later, NNK became the focal carcinogen in animal assays. 
Caffeine consistently showed inhibitory effects on NNK-induced lung tumorigenesis in 
murine models, independently of other components of black tea or green tea (Xu et al., 
1992; Chung et al., 1998; Lu et al., 2006). It also inhibited dibenzo[a,l]pyrene (DBP) 
transplacental carcinogenesis in the lungs of mouse offspring born to mothers 
administered with DBP (Castro et al., 2008). However, its inhibitory effect was 
confounded by its suppressive effects on metabolism and negative effect on body 
weight. The exact mechanism of the inhibition produced by caffeine is still not entirely 
known. One postulated mechanism stated that the increased metabolism of NNK or 
DBP in the liver due to caffeine-induced hepatic cytochrome P450 enzymes will result 
in the decreased bioavailability of the carcinogens to the lung (Chung et al., 1998; 
Castro et al., 2008;). Other mechanisms are possibly involved in the activities of 
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caffeine.  
In all the reports above, caffeine was given systemically (via i.p. injection or p.o.) or 
topically. In this study, caffeine (purchased from Sigma-Aldrich, St. Louis, MO) was 
delivered by aerosol inhalation in the hope of reducing systemic exposure to caffeine 
and removing the confounding effects mentioned above.  
 
Figure 5‐5 Caffeine treatment protocol.   
 
Figure 5‐6 Body weight  changes  of  caffeine‐treated mice  compared with mice  in  the  control 
group during treatment. Error bar: SE. 
 
Aerosolized caffeine was evaluated using a post-initiation protocol in a 
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B[a]P-induced A/J mouse model. Female A/J mice at 6 weeks of age were given two 
doses of B[a]P (100 mg/kg body weight, one week apart) by i.p. injection in 0.2 ml of 
tricaprylin. The mice were randomly divided into two groups, with 12 mice per group: 1) 
Aerosol control group (50% DMSO in ethanol); 2) Caffeine group (10 mg /ml). The 
treatment started two weeks after the second B[a]P injection. The aerosol procedure was 
the same as in the case of gefitinib and erlotinib. The mice were treated once a day, five 
days a week, for 19 consecutive weeks (Figure 5-5). Aerosolized caffeine did not 
negatively influence the body weight at this dose (Figure 5-6).  
Table 5‐2 Effects of aerosolized caffeine on tumor incidence, tumor multiplicity, and tumor load. 
Tumor multiplicity and tumor load are presented as mean ± SE.  
 Dose 
Incidence 
(%) 
Tumor 
multiplicity  
Inhibition 
(%) 
Tumor load 
(mm3) 
Inhibition 
(%) 
Control DMSO/EtOH 100 16.27 ± 1.15 - 3.65 ± 0.36 - 
Caffeine 10 mg/ml 100 11.08 ± 2.02 31.9* 2.03 ± 0.43 44.3* 
*: P < 0.05. The aerosol solvent control group was given 50% DMSO in EtOH.  
 
The incidence of lung tumors was 100% in the aerosol control group and the caffeine 
treatment group (Table 5-2). Aerosolized caffeine significantly reduced the tumor 
multiplicity and tumor load by 31.9% (P < 0.05) and 44.3% (P < 0.01). Aerosolized 
caffeine reduced the number of relatively large tumors in each category (Figure 5-7). It 
seems that caffeine could suppress tumor growth but was not able to inhibit tumor 
initiation.  
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Figure  5‐7 A,  Inhibitory  effects  of  aerosolized  caffeine  on  the  tumor multiplicity  and  tumor 
load.  B,  Tumor  size  distribution  in  the  control  and  caffeine‐treated  groups.  *:  P  <0.05. 
Inhibition rate percentage is labeled on top of the bars.   
 
The results are presented in Figure 5-7. This study showed that aerosolized caffeine 
partly, but significantly, inhibited the tumor multiplicity and the tumor load in the 
mouse lungs without decreasing body weight; it is indicated that inhibitory effect of 
caffeine on lung tumorigenesis is related to other mechanisms rather than by decreasing 
the body weight. Caffeine tended to accumulate in the blood. The serum level was about 
4 times higher than that in the liver and in the lung (Che et al., 2011). Consequently, 
aerosol delivery may be the solution to effectively increase the bioavailability of 
caffeine in the mouse lungs.  
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5.3 Anthocyanins and Protocatechuic Acid (PCA) 
 
Figure  5‐8  Flavylium  ion  backbone  of  anthocyanidins.  R1,  R2,  and  R3 could  be  –OH,  ‐H,  and 
–OCH3.   
 
Anthocyanins are a class of water-soluble highly pigmented flavonoids which could 
impart peculiar red-orange to blue-violet colors to many fruits and vegetables, such as 
berries, red grapes, purple sweet potatoes, and red cabbages. The produce appears red, 
purple, or blue according to the pH and the plant’s structural features (Hou et al., 2004; 
Li et al., 2012; Massela et al., 2012). The anthocyanins are glycosides of anthocyanidins. 
Complex glycosylation patterns result in hundreds of anthocyanins, but fewer than a 
dozen aglycones (anthocyanidins) are identified. Seven anthocyanidins - delphinidin, 
luteolinidin, cyanidin, petunidin, pelargonidin, peonidin, and malvidin - are found in 
commonly consumed plant food, containing the same flavylium ion backbone (Figure 
5-8). The bioactivity of the resulting anthocyanins may vary with the molecular 
structures. Diet rich in anthocyanins has been suggested to prevent from a variety of 
disorders, such as cancer, cardiovascular disease, aging, inflammation, diabetes, arthritis, 
and obesity, as well as bacterial infections (Hou et al., 2004; Aqil et al., 2012; Li et al., 
2012). PCA has demonstrated similar health benefits as anthocyanins. 
Protocatechuic acid (3,4-dihydroxybenzoic acid, PCA; Figure 3-4) is a simple 
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phenolic compound ubiquitously distributed in nature. PCA exists in many daily 
consumed foods, such as bran and grain, brown rice, fruits, nuts, and spices, as well as 
plant-derived beverages, and is also the biologically active component of some 
medicinal plants (reviewed by Tanaka et al., 2011; Masella et al., 2012). Although the 
concentration of PCA in fruits and vegetables is very low (PCA food content is 
summaried by Masella et al., 2012), complex polyphenols, such as anthocyanins, are 
good sources of PCA in vivo because PCA is the main metabolite of these polyphenols.  
The cancer chemopreventive activities of anthocyanins have been studied in vitro 
using multiple cancer cell lines and in vivo in animal models for esophageal, colon, skin 
and lung cancer. Many mechanisms have been proposed, including antioxidant effects, 
Phase II enzyme activation, anti-cell proliferation, induction of apoptosis, 
anti-inflammatory effects, anti-angiogenesis, anti-invasiveness, and induction of 
differentiation (reviewed by Wang and Stoner, 2008). Based on search results from 
Pubmed (pubmed.com), in vitro studies in cell lines are far more than prevalent in vivo 
studies in animal models. Low bioavailability might hinder the in vivo evaluation of 
anthocyanins because the amount of anthocyanins that reach the target tissue might be 
insufficient to have biological activity despite the strong effects in vitro. The 
chemopreventive effects of PCA have also been evaluated extensively in vitro (Yin et al., 
2009) and in vivo in several models of chemically induced carcinogenesis in laboratory 
animals (Reviewed by Tanaka et al., 2011). Most of the studies in animal models focus 
on carcinogenesis in the digestive system, and inhibition of tumorigenesis was observed 
when PCA was administered in the initiation phase and in the promotion/progression of 
carcinogenesis at doses of 200-2000 ppm in the diet (Tanaka et al., 2011). However, 
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there is only one report about lung carcinogenesis, and its disappointing result is that 
PCA did not inhibit NNK-induced lung tumorigenesis in mice (Mori et al., 1999). The 
authors did not provide an explanation for this result.  
Current studies on the chemopreventive effects of anthocyanins and PCA on lung 
carcinogenesis are not enough. There are still several questions: Does an anthocyanin or 
PCA inhibit lung carcinogenesis in vivo? Does the carcinogen or protocol matter? If 
there is an inhibitory effect, is it attributed to the intact agents or their metabolites? 
What is the main mechanism? If it does not have any inhibitory effect, is the lack due to 
the bioavailability or to the agents themselves? In this study, we started with the first 
question. Anthocyanins extracted from black raspberries and PCA were evaluated in a 
B[a]P-induced mouse model. Intact agents were delivered via aerosol inhalation to 
avoid complications from metabolites. The core hypothesis is that aerosol inhalation can 
increase the bioavailability of anthocyanins in the lung.  
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Figure 5‐9 A, PCA/anthocyanins treatment protocol; B, Body weight changes during treatment. 
Error bar: SE.   
Anthocyanins were prepared by Dr. Gary Stoner’s group from black raspberries 
(Wang et al., 2009) and are mainly glycosylated cyanidin. The molar percents of the 
three major anthocyanins were 12% cyanidin-3-O-glucoside, 34% 
cyanidin-3-O-(2G-xylosylrutinoside, and 53% cyanidin-3-O-rutinoside (Figure 3-4). 
PCA was purchased from Sigma-Aldrich (St. Louis, MO, U.S.). Female A/J mice at six 
weeks of age were given two doses of B[a]P (100 mg/kg body weight, one week apart) 
by i.p. injection in 0.2 ml of tricaprylin. The mice were randomly divided into three 
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groups with 12 mice per group: 1) Aerosol control group (50% DMSO in ethanol); 2) 
Anthocyanins group (5 mg /ml); 3) PCA group (12 mg/ml). The treatment started two 
weeks after the second B[a]P injection. The aerosol procedure was the same as 
described before. The mice were treated once a day, five days a week, for 19 
consecutive weeks (Figure 5-9).  
 
Figure 5‐10 Inhibitory effects of aerosolized PCA and aerosolized anthocyanins individually. A, 
Inhibitory  effects  of  aerolized  anthocyanins  and  aerosolized  PCA  on  tumor  multiplicity  and 
tumor load. B, Tumor size distribution in the control group, anthocyanins, and PCA groups. The 
tumor  number  clumps  the  tumors  in  all  the mice.  *:  P  <  0.05.  Inhibition  rate  percentage  is 
labeled on top of the bars. 
 
The body weight was monitored during the 19-week study. There was no significant 
difference between the treatment groups and the control group for the mice treated with 
anthocyanins or PCA (Figure 5-9). There was no mortality in all the groups. The tumor 
incidence was 100% for the aerosol control group. In the anthocyanins-treated mice, one 
out of twelve had no visible surface tumors in the lung, with a tumor incidence of 
91.7%. The PCA-treated group had the same tumor incidence of 91.7%.  
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Table  5‐3  Effects  of  aerosolized  anthocyanins  and  aerosolized  prococatechuic  acid  (PCA) 
individually  on  tumor  incidence,  tumor multiplicity,  and  tumor  load.  Tumor multiplicity  and 
tumor load are presented as mean ± SE.   
 
Dose 
mg/ml 
Incidence 
(%) 
Tumor 
multiplicity  
Inhibition 
(%) 
Tumor load 
(mm3) 
Inhibition 
(%) 
Control Solvent 100 16.27 ± 1.15 - 3.65 ± 0.36 - 
Anthocyanins 5 91.7 13.92 ± 3.24 14.5 2.54 ± 0.30 30.4 
PCA 12 91.7 8.50 ± 0.48 47.8* 2.01 ± 0.45 44.9* 
*: P < 0.01. The aerosol solvent control group was given 50% DMSO in EtOH.  
 
The results are summarized in Table 5-3. In the anthocyanins-treated group, the tumor 
multiplicity and tumor load were 13.92 ± 3.24 tumors and 2.54 ± 0.30 mm3 per mouse 
(n = 12), respectively. As presented in Figure 5-10 A, aerosolized anthocyanins showed 
marginal, but insignificant, inhibitory effects on both tumor multiplicity (reduced by 
14.5%) and tumor load (reduced by 30.4%). From the tumor size distributions (Figure 
5-10 B), we can find an indication that anthocyanins reduced the number of tumors with 
a diameter greater than 0.7 mm. Thus, the inhibitory effect of aerosolized anthocyanins 
is not conclusive. Higher doses of anthocyanins may be required to achieve significant 
inhibition.  
In the PCA-treated group, the tumor multiplicity and tumor load were 8.50 ± 0.48 
tumors and 2.01 ± 0.45 mm3 per mouse (n = 12). PCA significantly reduced the tumor 
multiplicity and tumor load, by 47.8% (P < 0.01) and 44.9% (P < 0.01), respectively. As 
shown in Figure 5-10 B, tumors with a diameter between 0.5 to 0.8 mm were reduced 
by PCA. It is suggested that the inhibitory effect of PCA on B[a]P-induced lung 
tumorigenesis at least partly depends on the intact PCA itself. There are two reasons that 
might explain the negative results in Mori’s study (Mori et al., 1999). One is the 
Chapter 5 Chemopreventive Effects of Natural Compounds via inhalation 
99 
difference between carginogens, and the other is that the amount of PCA in the bioactive 
form in the lung is insufficient. Pharmacokinetic and immunohistological studies are 
necessary to interpret the results. 
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Chapter 6 Chemopreventive Effects of the Combination of 
Aerosolized Budesonide and Dietary Polyphenon E① 
Lung carcinogenesis is a complex mixture of miscellaneous mutations and lesions at 
different stages of development. It is reasoned that a combination of multiple agents that 
target different pathways can enhance the inhibition of lung tumorigenesis and reduce 
adverse side effects. Thirteen combinations of agents were evaluated in this dissertation. 
Since aerosolized budesonide and aerosolized gefitinib were shown to inhibit 
B[a]P-induced tumorigenesis in the A/J mice consistently, these two agents were 
selected to be combined with other agents that were also effective. Additionally, other 
combinations, such as a combination of oral pioglitazone and aerosolized 
2-deoxy-D-glucose, which target the glucose metabolism, were also assessed in the 
mouse model. In this chapter, the combination of aerosolized budesonide and dietary 
polyphenon E is discussed in detail as an example of the combination group. Other 
combinations were briefly discussed in the Appendix.  
Budesonide is a synthetic glucocorticoid that has been used for the treatment of 
bronchial asthma and chronic obstructive pulmonary disease in inhalation therapy for 
over two decades. Budesonide as a single agent has been shown to prevent the 
formation of lung tumors in mice treated with smoke-associated compounds, such as 
Benzo[a]pyrene (Wattenberg et al., 1997; Wattenberg et al., 2000; Wang et al., 2003; 
Estensen et al., 2004; Balansky et al., 2006), vinyl carbamate (Pereira et al., 2002), and 
                                                              
① The manuscript has been prepared and will be submitted to Molecular Carcinogenesis.  
Chapter 6 Chemopreventive Effects of the Combination 
102 
4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanol (NNK) (Casto et al., 2011), per os 
(Pereira et al., 2002; Pereira et al., 2006; Wang Y et al., 2003; Balansky et al., 2006) and 
via inhalation (Wattenberg et al., 1997; Wattenberg et al 2000; Estensen et al., 2004; Fu 
et al., 2011).  
Polyphenon E (PPE) is a well-defined, pharmaceutical-grade mixture of green tea 
polyphenols that contains at least five catechins. Epigallocatechin-3-gallate (EGCG) is 
the most abundant catechin comprising 65% of PPE. PPE administered by diet (Clark 
and You, 2006; Zhang et al., 2010; Yan et al., 2006) and by aerosol, also significantly 
inhibited B[a]P induced lung tumorigenesis in A/J mice (Yan et al., 2007; Fu et al., 
2009). PPE in drinking water can also inhibit NNK-induced lung tumorigenesis in A/J 
mice (Lu et al., 2006). PPE and budesonide are capable of inhibiting tumorigenesis 
induced by multiple carcinogens associated with cigarette-smoking.  
The use of budesonide or PPE in combination with other agents is a new and 
emerging approach to lung cancer chemoprevention. There are four reports for 
budesonide and two for PPE. Inhaled budesonide combined with other agents, such as 
dietary myo-inositol (Wattenberg and Estensen, 1997) and orally-administered 
pioglitazone (Fu et al., 2011), achieved greater inhibitory effects in B[a]P-induced A/J 
mouse models. Budesonide in the diet combined with orally-administered R115777 
(ZarnestraMT) was shown to inhibit tumors in a vinyl carbamate-induced A/J mouse 
model (Alyaqoub et al., 2007). A recent study investigated the efficacy of concurrent 
and sequential administration of combinations of budesonide, suberoylanilide 
hydroxamic acid (SAHA), bexarotene (targretin), and atorvastatin on NNK-induced 
lung tumors in A/J mice and showed that budesonide combined with other agents 
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achieved a greater efficacy than did the individual agents (Casto and Pereira, 2011). 
Dietary PPE and aerosolized difluoromethylornithine (DFMO) combined were not more 
effective than PPE alone (Anderson et al., 2008). However, PPE in drinking water 
combined with atorvastatin in the diet synergistically inhibited NNK-induced lung 
tumorigenesis.  
In this study, we investigated the chemopreventive efficacy of the combination of 
aerosolized budesonide and dietary PPE. Budesonide (purchased from Sigma-Aldrich, 
St. Louis, MO) inhibited both tumor multiplicity and tumor load in our experiment as a 
single agent. With the addition of PPE (obtained from National Cancer Institute, 
Division of Cancer Prevention, Bethesda, MD), the combination led to greater efficacy. 
6.1 Experimental Methods 
6.1.1 Animal Bioassay 
Animals were housed with wood chip bedding in the environmentally-controlled, 
clean-air room with a 12-hour light-dark cycle at constant temperature and a relative 
humidity of 50%. Drinking water and diet were supplied ad libitum. Female A/J mice at 
seven weeks of age were given a single intraperitoneal (i.p.) injection of B[a]P (100 
mg/kg body weight) in 0.2 ml of tricaprylin. Two weeks after the B[a]P injection, the 
mice were randomly divided into 6 groups with 12 mice per group: 1) Aerosol control 
group (50% DMSO in ethanol); 2) Budesonide group (1.125 mg/ml); 3) Diet control 
group (AIN-76A diet, Dyets, Inc,. Bethlehem, PA, with 0.3% sugar); 4) PPE group 
(7.5g/kg diet); 5) Aerosol-and-diet control group; 6) Budesonide and PPE combination 
Chapter 6 Chemopreventive Effects of the Combination 
104 
group (bud + PPE). The treatment started two weeks after the B[a]P injection. The mice 
were treated once a day, five days a week for 20 consecutive weeks (Figure 6-1).  
 
Figure 6‐1 Treatment protocol. All treatment began two weeks after the i.p. injection of B[a]P. 
Aerosol groups were subjected to aerosol delivery treatment for two minutes per day, five days 
per week.  All  diet  control  groups  received  an  AIN‐76  diet with  3%  sugar  (wt/wt), while  all 
polyphenon  E  groups  received  an  AIN‐76  diet  with  3%  sugar  and  0.75%  PPE.  The  total 
treatment duration continued for 20 weeks. All mice were sacrificed 22 weeks after the B[a]P 
injection. 
 
All the solutions were fresh prepared on the same day they were used. The inhalation 
exposures were conducted using a custom-built nose-only exposure chamber. The mice 
were exposed to aerosols for two minutes by placing their noses into the cone of each 
sub-compartment. The body weight of the mice was recorded on the same weekday 
every week during the treatment. For the dietary PPE groups, mice were fed AIN-76A 
purified powder diet at a dose of 7.5 g/kg diet. A formulated diet was prepared using a 
KitchenAid mixer (St. Joseph, MI), mixing for at least 40 min twice a week, and the 
diet available in the cages was changed daily. 
6.1.2 Cell Proliferation Assay 
Human NSCLC cell lines A549 and H1299 were purchased from American Type 
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Culture Collection (Manassas, VA) and cultured in RPM1 1640 media with 10% fetal 
bovine serum (Gibco®, Invitrogen, Carlsbad, CA) and a penicillin and streptomycin 
cocktail (Gibco). All cells were cultured in a humidified incubator at 37 oC at 5% CO2. 
A549 and H1299 cells were seeded in 96-well plates (BD Falcon®, Franklin Lakes, NJ) 
at a density of 2×10³cells per well. Twenty-four hours after seeding, cells were exposed 
to a different concentration of budesonide, PPE, or the combination of the two as 
indicated for 24, 48, or 72 hr. The proliferation rate was measured by Alamar Blue, a 
cell variability indicator with resazurin as its active ingredient, which could be 
converted to the fluorescent molecule, resorufin, by active cells. Alamar Blue 
(Invitrogen, Carlsbad, CA) was added to the culture media at 10% of the media volume 
during the last 10 hr of the exposure period. Fluorescence was detected on a Synergy 
HT microplate reader (Biotek, Winooski, VT) using an excitation wavelength of 544 nm 
and an emission wavelength of 590 nm. 
6.1.3 Combination Effects Analysis 
Data for the combination effect analysis were obtained from experiments in two lung 
cancer cell lines, A549 and H1129. A linear model was used to test for combination 
effects of budesonide and PPE (i.e., antagonism, additivity, and synergy). The model is  
     ijkl i j ij k ifkly B P BP C e= + + + + , (6) 
where y is live cell numbers for the kth cell line and the lth replication, l = 1, 2, or 3; B 
is the budesonide effect, i = 1 or 0; P is the PPE effect, j = 1 or 0; C represents the 
difference between two cell lines, k = 1 for A549 and 0 for H1299; e is an error term. 
The statistical analyses were performed in R (www.r-project.org). 
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6.2 Results 
6.2.1 Inhibitory effects of aerosolized resveratrol on B(a)P-induced lung tumors 
in A/J mice 
We first determined the characteristics of the budesonide aerosols generated by our 
custom-made Collison type atomizer. The size distribution of budesonide aerosols from 
1.125 mg/ml solution was measured. The GMD was 0.065 μm, and the GSD was 1.8. 
The size falls in the window of breathable particles for mice to ensure as high a delivery 
efficiency as possible.  
The mass concentration in the exposure chamber was measured at 13.8 μg/L. The 
dose of budesonide to the animal was estimated to be 25 μg/kg body weight per day 
(calculated from a published method assuming that the average mouse body weight is 
25 g; ref: Wattenberg et al., 1997). The dose of PPE to the animal was estimated to be 
900 mg/kg body weight per day, assuming that the average mouse body weight is 25 g 
and one mouse consumes 3 gram of diet each day.  
At the end of the 22-week study, the body weight of the mice in the treatment groups 
were 21.9 ± 0.5, 26.6 ± 0.69, and 24.2 ± 1.08 g, for budesonide, PPE, and the 
combination group, respectively. The corresponding control groups (the aerosol control 
group, the diet control group, and the aerosol-and-diet control group) were 22.6 ± 0.47, 
25.6 ±1.28 and 24.6 ± 0.72 g, respectively. There is no significant difference in the body 
weight between the treatment groups and the control groups, which means that the 
treatment of budesonide and PPE did not cause systemic toxicity. 
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Figure 6‐2 Inhibitory effects of aerosolized budesonide, dietary polyphenon E and their combination 
on lung tumor multiplicity and tumor load. A, Dietary PPE (0.75 w.t.% in diet); B, Aerosolized 
budesonide (1.125 mg/ml, 2 min/day); C, The combination of aerosolized budesonide and dietary 
PPE; D, Decreased percentage of tumor multiplicity and tumor load by the three treatments. BUD: 
budesonide; PPE: Polyphenon E; Diet Ctrl: Diet control; Sol_Ctrl: Solvent control; Sol_Diet_Ctrl: 
Solvent and diet control. Inhibition rate percentage is labeled on the top of each bar. Error: SE.  
 
The tumor incidence rate in all the control groups and PPE group is 100%, while the 
incidence rate in the groups treated with budesonide, PPE, and their combination is 75%, 
100%, and 83.3% (Table 6-1), respectively. Tumor multiplicity and tumor load were 
both reduced in the treatment groups (Figure 6-2). As a single agent, aerosolized 
budesonide showed inhibitory effects on lung tumor multiplicity and tumor load 
compared with their own control groups. Budesonide decreased tumor multiplicity by 
55.2% (1.83 ± 0.28, n = 12) and tumor load by 66.7% (0.26 ± 0.09 mm3) compared with 
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the solvent control group in which, on average, tumor multiplicity and tumor load are 
4.1 ± 0.62 and 0.78 ± 0.17 mm3 (n = 11), respectively (Figure 6-2 B). However, PPE 
showed no significant difference from that of the diet control group with a 7.5 g/kg diet. 
B[a]P induced an average of 5.67 ± 0.94 and 6.45 ± 1.17 (n=11) tumors per mouse in 
the diet control group and PPE group, respectively. The average tumor load was 1.42 ± 
0.25 mm³per mouse in the diet control group, while the average tumor load in the PPE 
group was 1.35 ± 0.28 mm3(n = 12) (Figure 6-2 A).  
Table 6‐1 Effects of aerosolized budesonide, dietary polyphenon E and their combination on tumor 
incidence, tumor multiplicity, and tumor load. 
 
Tumor 
incidence 
Tumors 
multiplicity Inhibition Tumor load  Inhibition  
 (%) (mean±SE) (%) (mean±SE) (mm3) (%) 
SolCtrl 100 4.09 ± 0.62 - 0.78 ± 0.17 - 
BUD 75 1.83 ± 0.53 55.2* 0.26 ± 0.09 66.7* 
Diet Ctrl 100 5.67 ± 0.94 - 1.42 ± 0.25 - 
PPE 100 6.45 ± 1.17 -13.8 1.35 ± 0.28 4.9 
Sol_Diet_Ctrl 90.9 6.00 ± 1.00 - 1.58 ± 0.46 - 
BUD+PPE 83.3 2.08 ± 0.42 65.3* 0.2 ± 0.06 87.3* 
* P < 0.05. Abbreviation: SolCtrl: solvent control; BUD: budesonide; Diet Ctrl: diet control; PPE: 
polyphenon E; Sol_Diet_Ctrl: solvent+diet control.  
 
In the aerosol and diet control group, the B[a]P-induced lung tumor multiplicity and 
tumor load were 6.00 ± 1.00 (n = 11) and 1.58 ± 0.46 mm3, respectively. With the 
treatment of budesonide combined with PPE, tumor multiplicity and tumor load were 
reduced to 2.08 ± 0.42 (n= 12) and 0.20 ± 0.06 mm3, respectively. The combination of 
budesonide and PPE was more effective in preventing lung tumors than either drug 
Chapter 6 Chemopreventive Effects of the Combination 
109 
alone, inhibiting tumor multiplicity by 65.3% and tumor load by 87.3% (Figure 6-2 C). 
 
Figure 6‐3 Tumor size distribution in aerosolized budesonide, dietary Polyphenon E and their 
combination groups compared with the corresponding control groups.   
 
The tumor size distributions are shown in Figure 6-3. Aerosolized budesonide, 
individually, completely inhibited tumors greater than 1.0 mm and reduced the number 
of medium sized tumors (0.7-0.8 mm). The combination of the two agents also 
eliminated tumors greater than 1.0 mm and reduced the number of tumors with sizes 
from 0.7 to 1.0 mm (Figure 6-3). 
6.2.2 An additive inhibitory effect of budesonide and PPE on the proliferation 
of human lung cancer cells 
Human non-small lung cancer cells A549 and H1299 were exposed to budesonide or 
PPE. Our results showed that the proliferation of A549 and H1299 cells decreased 
significantly in a time-dependent manner following either 50 μM budesonide treatment, 
20 μg/ml PPE, or their combination. Additionally, at any time point, the combination 
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inhibited cell proliferation more effectively. 
 
Figure  6‐4 An additive combined effect of budesonide and polyphenon E in the inhibition of cell 
proliferation of human non-small lung cancer cells: A, A549 cell lines; B, H1299 cell lines. 
 
When cells were treated with the combination of budesonide and PPE, a strong 
growth-inhibition was observed (Figure 6-4). 50 μM budesonide inhibited proliferation 
to 48.4% in A549 cells and 61.6% in H1299 cells, while 20 μg/ml PPE inhibited the 
proliferation to 81.5% in A549 cells and 67.6% in H1299 cells. When the agents were 
combined (at the same dose as in individual dosing), proliferation rates decreased to 
32.9% and 40.0% in A549 and H1299 cells, respectively.  
Table 6‐2 Estimation of the combination effects of budesonide and polyphenon E 
 Estimate SE t-value Pr (>|t|) 
Budesonide 1.053  0.056  18.823  < 2e-16 *** 
Polyphenon E -0.237  0.079  -2.992  0.00383 ** 
Cell -0.132  0.079  -1.675  0.098  
Budesonide:Polyphenon E -0.120  0.079  -1.518  0.133  
*** < 0.001, ** < 0.01, * < 0.05. 
 
To further demonstrate the combinational effects of these two agents, the linear model 
was used. As shown in Table 6-2, both budesonide and PPE had significant effects in 
inhibiting cell growth, but there was no agent interaction effect. Thus, the two agents 
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exhibited independent, additive inhibitory effects on cell growth. 
6.3 Discussion 
Lung carcinogenesis is most likely associated with multiple pathways and steps. Thus, 
using combinations of multiple agents that work on different pathways or steps is a 
promising strategy and has advantages over the single-agent strategy. First, 
combinations of two or more agents may lead to additive or synergistic effects on 
tumorigenesis inhibition. Second, combinations of agents allow lower doses of one or 
more agents in the combination to minimize potential adverse side effects.  
Many mechanisms have been proposed for the chemopreventive efficacy of 
budesonide, but none of them have been identified. It is suggested that budesonide 
exerts its effects through growth arrest via Mad2/3 and through apoptosis via Bim/Blk 
and by inference caspase-8/9 (Yao et al., 2004). Moreover, budesonide prevented DNA 
hypomethylation (Tao et al., 2002; Wang et al., 2003; Pereira et al., 2006) and protected 
the lung from environmental-cigarette-smoke-induced alterations of microRNA 
expression (Izaotti et al., 2010). The mechanisms of PPE’s chemopreventive efficacy of 
lung carcinogenesis have been proposed based on studies with EGCG, which is believed 
to be the most active compound in PPE in cell lines (Yang et al., 2009), but recent 
studies have also shown that the preventive efficacy of EGCG on mice lung 
tumorigenesis requires the presence of other tea catechins in both dietary and aerosol 
administration (Fu et al., 2009; Zhang et al., 2010). PPE can interact and bind with 
multiple proteins (Bode and Dong, et al., 2009) to arrest or trigger signaling or 
metabolic pathways that lead to the inhibition of carcinogenesis (reviewed in Yang et al., 
Chapter 6 Chemopreventive Effects of the Combination 
112 
2009; Bode et al., 2009; Kanwar et al., 2012). That budesonide and PPE act by different 
mechanisms provides the rationale for the combination of the two agents.  
Moreover, budesonide is shown to be hepatotoxic in murine models. Orally-dosed 
budesonide at 2.4 mg/kg in diet (equivalent to 288 μg/kg body weight, assuming that 
one mouse with a body weight of 25 g consumes 3 g of diet a day) for 6 weeks was 
shown to induce intense microRNA variations in the liver of mice (Izzotti et al., 2010). 
Budesonide in the drinking water at 50 μg/kg body weight was tumorigenic in male rat 
livers (Ryrfeldt et al., 1992). PPE at a high dose of 2000 mg/kg body weight p.o. is toxic 
in the mouse (Chang et al., 2003). However, PPE has poor bioavailability, and high 
doses are required for its efficacy in the rodent (Chen et al., 1997; Lamber et al., 2003). 
Adverse side effects should be avoided for chemopreventive purposes. Therefore, the 
combination of these two agents at lower doses could potentially reduce the adverse 
side effects with similar or even stronger efficacy compared with the individual agent. 
In the present study, we studied the combination of budesonide and PPE both in vitro 
and in vivo. The in vitro test using human cell lines A549 and H1299 provides evidence 
that these two agents exhibit independent and additive inhibitory effects on tumor cell 
growth. In vivo, budesonide was administered by aerosol to the mice, which has been 
demonstrated to inhibit lung carcinogenesis individually, and PPE was given in the diet. 
Aerosolized budesonide (1.125 mg/ml) inhibited tumor multiplicity and tumor load by 
55.2% and 66.7%, while dietary PPE (7.5 mg/kg diet) did not show its inhibitory effects. 
When the two agents were combined, the combination inhibited tumor multiplicity by 
65.4% and tumor load by 87.3% without exerting an additional impact on mouse body 
weight compared with the control group. It is noticeable that budesonide aerosolized 
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with the same nebulizer at a higher dose (2.25 mg/ml, 2min) inhibited tumor load in the 
same mouse model by 78% (Fu et al., 2011). The efficacy of the combination is slightly 
higher than budesonide alone at a higher dose. It is reported that dietary PPE inhibited 
tumor load dose-dependently by 65% and 78% at 0.5 and 1.0 mg/kg diet, but showed no 
effect on tumor multiplicity (Yan et al., 2006). However, in our study, PPE showed 
minor inhibitory effects on tumor load. The reason is unknown and might be due to the 
variations in animals and batches of agents. Compared with the reported results, the 
combination still has the advantage. Thus, we have demonstrated that the combination is 
more effective than either agent alone in decreasing tumor multiplicity and tumor load.  
In humans, inhaled budesonide does not show inhibitory effects on tumors as strongly 
as in the mice. In a randomized Phase II clinical trial, inhaled budesonide (Pulmicort 
Turbuhaler®) administered to current cigarette smokers with bronchial dysplastic 
epithelium had no effect on the regression of bronchial dysplastic lesions or on the 
prevention of new lesions in current smokers compared with the placebo group, but it 
did result in a modest decrease in p53 and Bc/II protein expression in bronchial biopsies 
(Lam et al., 2004). Another randomized Phase II trial (Lazzeroni et al., 2010; Veronesi 
et al., 2011) of inhaled budesonide in high-risk individuals with CT screen-detected 
lung cancer revealed a significant effect of budesonide on the regression of existing 
target nodules by per-lesion analysis but no effect on new lesions. The results from 
these randomized clinical trials suggested that budesonide had some activity in 
precancerous lesions. Consequently, combination of these agents to produce a stronger, 
collaborative effect is a promising strategy for the future. 
In summary, combined aerosolized budesonide and dietary PPE was demonstrated to 
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be more efficacious in inhibiting lung tumors than the individual agent. Their additive 
effects were observed both in vivo and in vitro. The low dose combination of these two 
agents is preferable for chemoprevention use since the low dose combination exhibits 
stronger inhibitory effects on tumor multiplicity and tumor load with no observable side 
effects. 
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Chapter 7 Evaluation of Drug Particle Deposition in the 
Mouse Lung 
The systemic dose is the quantity of the drugs administered into the body. In the 
aerosol delivery system, the systemic dose is the total amount of drugs (mass or amount 
of substances) inhaled by the mouse, measured by mass or molars of the drug per kg of 
body weight. For the gavage and the parenteral administration, the systemic dose is 
explicit, and could be calculated accurately from the drug concentration in the 
formulation and the fed/injected/infused volume. For the drug mixed in the diet or 
dissolved in the beverage, the systemic dose could be estimated when the daily 
consumption of diet or beverage is assumed based on observation. The consumption 
might be gender and species specific but should not vary considerably for the 
commonly-used animal models. However, for the aerosol delivery system, the 
relationship between the systemic dose and the operative parameters, mainly the 
solution concentration and the exposure time, is implicit and device-dependent. Thus it 
is necessary to characterize the specific experimental setup and aerosol generation 
device used in the aerosol delivery system and, to establish the relationship between the 
systemic dose and the operative parameters. The dose for aerosol delivery could be 
estimated from the aerosol concentration, the exposure time, and the respiratory minute 
volume of the lab animals (Section 3.2 ).  
The efficacy of the drugs in the lung depends on the level of the bioactive form of the 
drug in the lung. The lung level is determined by the amount of drugs that finally reach 
and stay in the lung, measured by the mass or moles of the drug per unit mass of the 
lung. The measurement method for the mass in the lung is the same for all the 
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administration routes, but the factors that influence the lung level in the cases of oral or 
aerosol administrations are different. For oral administration, the lung level depends on 
metabolism and clearance, thus the formulation, i.e. the molecular structure or the drug 
carriers (such as nanoparticles and polymers), is critical to oral administration. 
Conversely, for aerosol administration, the lung level is not quite related to the 
metabolism. The properties of the drug particles (clusters of drug moleculars) and 
transport behavior of the particles inside the respiratory tract determine the lung 
deposition of the drug aerosols and, subsequently, the lung level of the drug.  
So far, many agents have been evaluated using the current experimental set-up 
(Figure 3-2), and encouraging results were achieved. In the current delivery system, the 
only two operable parameters are solution concentration and exposure time. The 
relationship between the operable parameters and the lung deposition has not been 
established for the current system. Therefore, it is necessary to characterize the system 
to better understand it and for to eventually improve on its design.  
Concerning the particle mass deposition in the mouse lung, there are three levels of 
information to obtain with ascending resolution: the total mass deposited in the lung, the 
mass deposited in each lung lobe, and the mass distribution pattern in the lung. In this 
chapter, the total mass deposited in the lung was measured as the first step to give an 
insight into the problem.  
7.1 Materials and Methods 
7.1.1 Particle generation and characterization 
The anticancer drug gefitinib was selected as the model medicine. The aerosol mass 
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concentration in the exposure chamber and the mass deposited in the lung were 
measured with varied solution concentrations and exposure time. The testing matrix is 
laid out in Table 7‐1. 
Table 7‐1 Testing matrix for the current aerosol delivery system.   
  Solution Concentration, mg/ml 
   1   2.5   7.5   15   25   50  
Exposure 
Time, min 
10 min    √   
15 min √ √ √  √ √ 
20 min    √   
 
The custom-built Collison atomizer was used to generate polydispersed particles. The 
applied air pressure was 20 psi. This same atomizer and conditions were used in 
previous animal bioassays as the aerosol generator. Gefitinib powder was dissolved in 5 
ml 50% DMSO in ethanol with concentrations of 1.0, 2.5, 7.5, 25, and 50 mg/ml, which 
covers the frequently-used concentration range in the animal bioassays, to evaluate the 
effect of solution concentration. In addition, two vials of 5 ml solutions at 15 mg/ml 
were also prepared to evaluate the effect of the exposure time. The aerosol mass 
concentration was estimated using the gravity method. The aerosol residue was 
collected in the filter media at the exit of the animal exposure chamber. The filter media 
was conditioned under a vacuum overnight before and after the particle loading, and 
then weighed. The air flow rate through the filter media was controlled at 2.0 liters per 
minute with an orifice.  
The single-capillary electrospray technique was used to generate monodispersed 
particles. Three sizes were selected: 50, 100, and 200 nm. Since the mass throughput of 
the single-capillary electrospray is very low, the gravity method is not sensitive enough 
for the measurement. A piezobalance dust monitor (KD12, Kanomax, Japan, Inc.) was 
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used to measure the aerosol mass concentration in the chamber.  
7.1.2 Animal experiment and tissue assay methods 
Female NIH-Swiss mice were used in this study. The mice were divided into seven 
groups (Iressa1, Iressa2.5, Iressa7.5, Iressa25, Iressa50, Iressa10min, and Iressa20min), 
corresponding to seven testing conditions, with four mice per group. The mice were 
exposed to drugs with different aerosol concentrations in the chamber and for a 
designated duration. They were sacrificed immediately following the aerosol treatment. 
Blood was collected from their retro-orbital sinuses. The whole lung was harvested 
from each mouse and snap-frozen in liquid nitrogen after removing the trachea and 
blood. The liver, spleen, and kidney were also harvested for future analysis. To separate 
the plasma from the hemoglobin, the blood samples were centrifuged at 13,200 rpm for 
15 min. The plasma was transferred to another labelled eppendorf tube and stored in -80 
oC. The lung and other organs were also stored at -80 oC for future analysis.  
The lung tissue was weighed, frozen in liquid nitrogen, and crushed with a pre-cooled 
tissue pulverizer. The crushed tissue was collected in an eppendorf tube containing 200 
μl of DMSO and vortexed to form a uniform homogenate. After the addition of 500 μl 
of acetonitrile, the samples were vortexed again for two minutes and centrifuged at 
13,200 rpm for 15 min at 4 oC to precipitate the proteins. The supernatant was removed 
and dried using nitrogen and then reconstituted with 200 μl of methanol. The plasma 
was processed in the same way as the lung tissue homogenate. The mobile phase 
consisted of 50 mM ammonium acetate (pH = 2.2) and acetonitrile, with a ratio of 80:20. 
The flow rate of the mobile phase was 1 ml/min. The detection wavelength was 348 nm.  
Gefitinib was quantified by HPLC. The HP 1100 series HPLC system consisted of an 
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autosampler, a quaternary pump, a thermostatted column compartment, and a UV 
detector (Agilent Tech, Santa Clara, CA). An Agilent Zorbax SB-C18 (4.0 × 150 mm, 
3.5 μm) column was used for separation. 
7.2 Results and Discussion 
For each testing condition listed in Table 7-1, the mass concentration of gefitinib 
aerosols was estimated. The results are shown in Table 7-2 and Figure 7-1.  
 
Figure 7‐1 Mass concentration of gefitinib aerosols in the animal exposure chamber. 
 
The aerosol mass conentration positively correlated with the solution concentration, 
and the correlation was almost linear. The aerosol mass concentration ranged from 12.3 
to 179.8μg/L. The maximum aerosol concentration was achieved with a solution of 50 
mg/ml, which was the solubility limit in the current solvent system (50% DMSO in 
ethanol). For the 15 mg/ml solution, the mass concentration was measured for 10 min 
and 20 min as a simple verification for the measurement method. The aerosol mass 
concentrations were 0.160 and 0.180 μg/L for 10 min and 20 min, respectively. The two 
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values were close to each other, and the deviation was acceptable.  
Table  7‐2  Mass  concentrations  of  gefitinib  aerosols  in  the  animal  exposure  chamber  with 
varied solution concentrations and exposure time using the custom‐made Collison atomizer. 
Group 
Filter 
Loading 
μg 
Aerosol 
Concentration 
μg/L 
Solution 
Concentration
mg/ml 
Consumed 
Solution 
Volume,ml
Consumed 
Mass, mg 
Solution 
Utilization 
Efficiency‡, 
% 
Iressa1*  370  12.3    1.0    4.00  4.0    9.2   
Iressa2.5*  380  18.0    2.5    3.50  8.8    4.3   
Iressa7.5*  2340  78.0    7.5    3.75  28.2    8.3   
Iressa 25*  7680  256.0    25.0    3.00  75.0    10.2   
Iressa50*  18120  604.0    50.0    3.25  162.5    11.2   
Iressa10min†  3190  159.5    15.0    2.50  37.5    8.5   
Iressa20min†  7190  179.8    15.0    4.25  63.7    11.3   
*: The number stands for the solution concentrations. For example, Iressa1 means the solution 
concentration is 1 mg/ml, and so on. The dosing time, or exposure time, was 15 min. †: The solution 
concentration is 15 mg/ml, and the exposure time is 10 and 20 min, respectively. ‡: The utilization 
rate was calculated by (aerosol mass concentration × exposure time × flowrate)/Consumed mass × 
100%. 
 
The liquid consumption was also measured by gross observation. A 5 ml solution was 
added to the atomizer in each case. 3.5 ml on average was consumed during a 15 min of 
atomization process, and the liquid comsuption did not correlate with the solution 
concentration. A 2.5 ml and a 4.25 ml solution was sprayed out for a 10 min and a 20 
min of atomization, respectively. Compared to the aerosol loaded in the filter media, 
only 9.0% of the drugs on average consumed by the atomizer were utilized. The results 
suggested that most of the drug particles were lost in the tubings and the diffusion 
dryers before they entered the chamber. 
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Table  7‐3  The  concentration  and  total  deposition  of  gefitinib  in  the  mouse  lung  for 
polydispersed particles.   
Group  Lung 
Concentration, 
nmol/g tissue 
Lung 
Weight, g 
Total  lung 
deposition, 
μg 
Plasma 
Concentration
, nmol/ml 
Body 
weight, g 
Iressa1  1.20±0.24    0.21±0.01  0.11±0.02  0.03±0.03  25.8±0.8 
Iressa2.5  2.63±0.64  0.17±0.02  0.19±0.05  0.18±0.07  26.0±1.6 
Iressa7.5  6.10±1.01  0.17±0.02  0.46±0.07  0.40±0.11  26.0±1.2   
Iressa 25  14.16±5.19  0.18±0.02  1.06±0.32  0.77±0.09  26.6±1.0   
Iressa50  24.22±8.63  0.16±0.00  1.74±0.62  0.96±0.18  26.5±0.9   
Iressa10min  11.04±1.36  0.18±0.03  0.87±0.08  0.71±0.06  26.7±1.5   
Iressa20min  16.52±2.52  0.17±0.01  1.23±0.18  1.00±0.13  25.8±0.5   
 
 
Figure  7‐2  Concentrations  of  gefitinib  in  the  lung  or  plasma  as  a  function  of A, B,  solution 
concentrations, and C, D, exposure time.   
 
The lung concentration and plasma concentration were measured, and the total 
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amount of gefitinib in the lung and blood was estimated. The results were shown 
in Figure 7-2 and Table 7-3. The concentration of gefitinib in the lung rose with 
increased solution concentration nonlinearly, but monotonically. So did the 
concentration in the plasma. The concentration in the lung was 15-25 times higher than 
in the plasma. This proved that the majority of the drug delivery via aerosol inhalation 
reached the lung, with only a miniscule portion entering the circulation following 
treatment. The concentration in the lung and plasma also increased with longer exposure 
time. However, the concentrations did not double with doubled exposure time. The total 
mass deposition for each testing condition was also shown in Table 7-3. 
Table 7‐4 The mass concentration of gefitinib aerosols  in  the animal exposure chamber with 
varied  solution  concentrations  and  exposure  time  using  the  single‐capillary  electrospray 
nebulizer.   
Group  Aerosol 
Concentration 
μg/L 
Solution 
Concentration
mg/ml 
Consumed 
Solution 
Volume,ml
Consumed 
Mass, mg 
Solution 
Utilization   
Efficiency, % 
50 nm  0.15    0.42 0.39  0.16  142.86   
100 nm  0.18    1.66 0.41  0.67  48.36   
200 nm  0.6    12.6 0.60  7.56  11.90   
 
For the monodispersed particles, the aerosol mass concentrations were 0.15, 0.18, and 
0.6 μg/l for 50, 100, and 200 nm aerosols, respectively. The solution utilization 
efficiency for 50 nm measured higher than 100%, probably due to an overestimation of 
aerosol mass concentration in the chamber. The average lung deposition, for the 50, 100, 
and 200 nm case were 0.047, 0.087, and 0.103 μg, respectively.  
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Figure  7‐3  Size  distribution  of  the  generated  gefitinib  aerosols. A, B,  and C, monodispersed 
aerosols generated by electrospray (ES) with an MMAD of 50, 100, and 200 nm. A, ES 50; B, ES 
100; C, ES 200; D, polydispersed aerosols generated with a custom‐built Collison atomizer. The 
solution was 15 mg/ml, and was atomized at 20 psi. The shape of the size distribution for the 
other solutions was similar to the one shown in D, with a shifted MMAD.   
 
The delivery efficiency for the custom-built Collison atomizer fluctuated from 10 to 
20% for different testing conditions (Figure 7-4 A). The 2.5 mg/ml solution had the 
highest delivery efficiency. The variation of the delivery efficiency might be a result of 
the shift in the mass mean diameter (MMD) of the aerosols, although the aerosols 
generated by the Collison atomizer were polydisperse. The MMD for a 2.5 mg/ml 
solution was around 120 nm (geometric standard deviation was 1.9). The delivery 
efficiency for the electrospray nebulizer is higher than that of the Collison atomizer 
Chapter 7 Evaluation of Drug Particle Deposition in the Mouse Lung 
125 
(Figure 7-4 B). The putative peak appeared at 100 nm. The combined results of the two 
generators suggested that 100 nm or so might be the optimal size for the maximum 
delivery efficiency.  
 
Figure 7‐4 Delivery  efficiency  for  the  custom‐built Collison  atomizer  and  the  single‐capillary 
electrospray system. The delivery efficiency is defined as the mass deposited in the lung/dose 
(Zhang et sl. 2011). 
 
The aerosol mass concentration and the lung deposition measured in this work made 
it possible to compare the aerosol inhalation method to other administration routes, 
providing basic information for future improvements. The Collison atomizer has two 
advantages: high mass throughput and relatively simple setup. The disadvantages are 
the low delivery efficiency and the lack of delivery accuracy due to polydispersity of the 
aerosols. Conversely, single-capillary electrospray has a higher delivery efficiency and 
probably a higher delivery accuracy as well, but the low mass throughput is the 
bottleneck. Obviously, monodispersed particles with a controlled size are more desirable 
for drug delivery. Therefore, developing a novel electrospray system with a high mass 
throughput is both necessary and urgent.  
Besides the improvements in the nebulizer, system optimization is equally important. 
At present, the custom-built Collison atomizer is still the primary aerosol generator in 
the animal bioassays. The tubing and desiccant/scrubber system needs to be optimized 
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to overcome the low efficiency of solution utilization. 
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Chapter 8 Dissertation Accomplishments and 
Recommendations for Future Work 
8.1 Summary of accomplishments 
In this dissertation, a broad range of agents were evaluated, either alone or combined, 
for their chemopreventive effects on lung tumorigenesis. These agents include synthetic 
inhibitors, plant-derived natural compounds, anti-inflammatory drugs, cytokines, etc. 
Their chemopreventive effects were examined. Throughout this process, the advantages 
of aerosol administration over conventional delivery methods were emphasized. The 
accomplishments of this study are summarized accordingly. 
An aerosol delivery system, consisting of a custom-built Collison atomizer, diffusion 
dryers and/or scrubbers, a nose-only mouse exposure chamber, an orifice, and a vacuum 
pump were used to deliver potentially chemopreventive agents in the form of aerosols to 
the mouse via inhalation. Eight single agents and one combination of agents were 
evaluated using the post-initiation protocol in female A/J mice.  
The eight single agents include four small molecular inhibitors and four natural 
compounds from plant sources. The four inhibitors are gefitinib, erlotinib, lapatinib, and 
wortmannin. Small molecular inhibitors have clear and specific mechanisms. The 
studies showed that gefitinib and erlotinib, two EGFR tyrosine kinase inhibitors (TKIs), 
consistently inhibited B[a]P-induced lung tumorigenesis in A/J mice. Aerosol delivery 
avoided the cutaneous side effects commonly found in this type of inhibitors. No visible 
skin alteration was observed. The pharmacokinetic study showed that aerosol delivery 
held an advantage over oral administration to deliver more or equivalent amount of 
agents into the mouse lung at a relatively low dose. Lapatinib, a dual inhibitor of EGFR 
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and Her2/neu, was studied in vivo as a chemopreventive agent for lung carcinogenesis 
for the first time to the best of our knowledge. Lapatinib delivered either via inhalation 
or via oral gavage showed significant inhibitory effects on tumor load, and aerosolized 
lapatinib also inhibited tumor multiplicity. Wortmannin is a highly potent PI3K inhibitor 
but was abandoned in clinical evaluation due to its toxicity and poor pharmacokinetic 
properties. This study compared the efficacy and toxicity when wortmannin was 
delivered via oral gavage and via inhalation, and demonstrated that aerosolized 
wortmannin is as potent as orally-dosed wortmannin but with reduced adverse side 
effects. Aerosol delivery is a worthy strategy to potentially revive wortmannin-like 
agents, which are highly toxic or poorly metabolized when administered orally.  
The four natural agents are resveratrol, caffeine, anthocyanins, and protocatechuic 
acid (PCA). The natural agents usually have nonspecific mechanisms and tend to react 
with or bind to multiple sites of action. The chemopreventive effects of resveratrol and 
caffeine on lung tumorigenesis are debatable based on reported data. In this study, 
aerosolized resveratrol has been shown to inhibit B[a]P- and VC- induced tumorigenesis 
in the mouse lung. The pharmacokinetic profile of resveratrol demonstrated that the 
aerosol route is a better way to deliver resveratrol, which may have a fast blood 
clearance rate in vivo. Aerosolized caffeine also showed significant inhibitory effects on 
tumor multiplicity and tumor load. The results were not confounded by the negative 
effects of caffeine on the body weight, since the mice treated with aerosolized caffeine 
maintained a similar body weight to the control group. Anthocyanins are a class of 
compounds with ubiquitous existence in nature, and are one of the main sources of PCA 
in the human body. Anthocyanins marginally inhibited lung tumorigenesis in the mouse 
model, whereas PCA showed significant inhibitory effects on tumor load and tumor 
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multiplicity. 
From the evaluation of the single agents, the advantages of aerosol delivery were 
demonstrated. Specifically for the agents with systemic toxicity and /or poor metabolic 
profiles, aerosol delivery helped to reduce the dose, minimize the toxicity, and 
maximize the amount of drugs in the lung.  
The combinational treatment of aerosolized budesonide and dietary polyphenon E 
were studies in the mouse model. An in vitro study showed that budesonide and 
polyphenon E have additive effects in two human cancer cell lines, A549 and H1129. 
An in vivo study showed that the combination of aerosolized budesonide and dietary 
polyphenon E had stronger inhibitory effects on tumor load and tumor multiplicity than 
the single agent. The study provided evidence that treatment with a combination of 
multiple agents that act on different mechanisms is a promising approach to lower the 
single agent dosage and the toxicity as well, and enhance the inhibitory effects on 
tumorigenesis.  
More single agents and other combinational treatments are summarized and discussed 
in the Appendix.  
For a better understanding of the current aerosol delivery system, the dose and mass 
deposition of the drug in the mouse lung were measured. Establishing relationship 
between the dose and operation parameters, specifically the solution concentration and 
the exposure time, were established and could be used to compare with other 
administration routes. Polydispersed particles were generated with the custom-built 
Collison atomizer. The aerosol mass concentration in the chamber increased linearly 
with the increasing solution concentration. The mass deposited in the mouse lung also 
increased with the increasing solution concentration monotonically, but in a non-linear 
Chapter 8 Dissertation Accomplishments and Recommendations for Future Work 
131 
manner. Longer exposure time lead to a higher dose and more mass deposited in the 
lung. However, the drug utilization efficiency, as well as the delivery efficiency, was 
quite low. The 2.5 mg/ml solution, which leads to an MMAD of 120 nm, had the highest 
delivery efficiency among other solutions. To further investigate the influence of 
particle size, monodispersed particles were generated and used. It was found that 
particles with an MMAD of 100 nm had the highest delivery efficiency, which seemed 
to be in agreement with the testing results for the polydispersed particles.  
8.2 Recommendations for future work 
In this dissertation, most of the work focused on the evaluation of agents in the 
animal bioassay. However, the bioassay is only the first step, and is accompanied by 
multiple unknowns, and followed by more questions. Chapter 2 reviews the three key 
factors for designing a sound chemoprevention an animal bioassay: the agent, the 
animal, and the biomarker (introduced but not involved in depth). Furthermore, to study 
aerosol administration for chemoprevention in animal bioassay, other factors should be 
added – technologies of aerosol generation and tranportation. In this chapter, the 
discussion or recommendation for future work will start from the accomplishments and 
lessons learned from the finished bioassays, focusing on the four key factors mentioned 
above.  
8.2.1 Pharmacokinetics 
One of the hypotheses tested in this dissertation is that aerosol delivery is capable of 
delivering the drugs directly into the lung, reducing exposure of other healthy organs. 
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For most of the agents discussed in Chapter 4 and Chapter 5, this statement is implied, 
but not explicitly addressed. Only the pharmacokinetic data can provide direct evidence. 
A comparison between the oral route and pulmonary route is preferred. Upon a literature 
search, there are only limited pharmacokinetic studies on pulmonary administration in 
mice. More published studies reflect the pharmacokinetic data of orally administered 
drugs than inhaled ones, yet not all of the drugs were studies. Therefore, it is necessary 
to measure the pharmacokinetics of the inhaled drugs. In this dissertation, only three of 
the testing agents, gefitinib, erlotinib, and resveratrol, had time-concentration curves 
and the steady-state lung and plasma concentration measured for aerosol delivery. 
Currently I’m working on the measurement of the steady-state concentration of four 
other drugs, lapatinib, wortmannin, anthocyanins, and PCA, in lung and plasma, via oral 
gavage and aerosol inhalation. The time-concentration curves of the lung and plasma 
are necessary for these agents, as well as for caffeine.  
The current workflow is to test the in vivo efficacy of a drug in an animal model first 
and whether the pharmacokinetic study will be carried out or not depends on the 
efficacy of the agent. The drug with a higher efficacy has a higher priority. The safest 
workflow measures the pharmacokinetics and toxicity of the agent before the agent is 
tested for its efficacy, if time and cost allowes.  
A more in depth analysis requires assistance from chemists and pharmacologists. Not 
only the intact drugs, but also the metabolites and related proteins, are part of the 
pharmacokinetic study.  
8.2.2 Biomarkers Analysis 
The biomarker analysis could be both explanatory for the animal bioassays alone and 
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predictive for the clinical trials. Positive results obtained from animal bioassays are not 
enough for an agent to be a candidate for clinical trials. For an agent to be a candidate, 
an appropriate biomarker – instead of a lung tumor – is needed as an endpoint to begin 
Phase II chemoprevention trials. The ideal condition might be to find a fingerprint 
biomarker for each type of lung cancer or to find a fingerprint biomarker for a certain 
agent. However, either one is difficulty.  
 The carcinogenesis is generally related to alterations in two distinct pathways: the 
suppression/deactivation of apoptosis and the promotion of proliferation. The efficacy 
of an agent is related to reversing this directions: the induction of apoptosis and the 
suppression of proliferation. Two approaches to biomarker analysis were discussed in a 
review of lung cancer chemoprevention (Dragnev et al., 2012). One is called a 
‘window-of-opportunity model’, which is more like a ‘fixed-spectrum’ method and 
focuses on the effect of the agent. There are several pre-selected candidates for this 
approach, which are expected to be related to the efficacy and the mechanism of the 
agent. In my opinion, this approach is suitable for the agents with known mechanisms. 
The other approach focuses on the effect of carcinogenesis and looks for alerations in 
several pre-selected relavent pathways. This approach is more like a ‘scanning-spectrum’ 
method and might be suitable for agents with unclear mechanisms or effects. Either 
approach has risks. For the first approach, even the agents with clear molecular targets 
may encounter confounding conditions in data interpretation, such as gefitinib which 
was discussed in Section 4.1 . Gefitinib is an EGFR inhibitor which is supposed to 
inhibit the phosphorylation of EGFR, and consequently the level of EGFR expression 
and level of EGFR phosphorylation are considered to be suitable biomarkers. 
Unfortunately, it seems that neither EGFR overexpression or EGFR mutation occurred 
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in the B[a]P-induced lung tumors in A/J mice (data not shown in this dissertation). Then 
the expected biomarkers of gefitinib did not work, although gefitinib did inhibit lung 
tumorigenesis in the same model. Thus, in this case, the second approach may help to 
explore other mechanisms of gefitinib besides the commonly known one as an 
EGFR-TK inhibitor. The related limitations of the first approach in clinical trials include 
recruitment difficulties. However, the second approach may provide too many 
biomarkers, making it difficult to gauge. I also questioned that this method may risk 
falsely relating one biomarker with the efficacy and/or the mechanism of the agent.  
In brief, a biomarker analysis is necessary to give insight into the mechanisms of the 
agents and to provide endpoints for future clinical trials. 
8.2.3 Design and Analysis of Drug Combinations 
For the combination treatment, the concept and hypothesis are attractive, but the 
details should be carefully designed. The best example of suitable combination 
treatment probably may come from nature, such as polyphenon E and traditional 
Chinese herb medicines. Understanding the interactions of single agents when 
combined is a complex process, rather than a simple mixture. A screening strategy is 
necessary for the experimental design. What agents could be combined together? What 
dose level could maximize the efficacy? What type of administration route is proper for 
each agent? Should they be administered concurrently or sequentially? All of these 
questions need answers, or at least considerations, before a combination group could be 
tested in the animal model. Statistical methods may bring some new insights to the 
experimental design of animal assays. 
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8.2.4 Improvement in Aerosol Instrumentations 
Through animal studies, the current aerosol delivery system has been proven to be 
effective in delivering the agents directly into the mouse lung. However, as indicated in 
Chapter 7, the drug utilization and delivery efficiency were both very low. The whole 
system requires improvement in both the particle generation and the mass transfer. The 
desired particle generation technique should have the capability to generate enough 
particles with controllable sizes and physiochemical properties. At present, neither the 
Collison atomizer nor the single-capillary electrospray system could satisfy this 
requirement. Therefore, it is necessary to discover and develop novel particle generation 
methods. In terms of mass transfer in the aerosol delivery system, the tubings and the 
diffusion dryers/scrubbers should be optimized to minimize particle loss in the system 
for future applications. Since the aerosol delivery process is more device-dependent, it 
is necessary to characterize the specific system before it is used in drug screening or for 
any evaluation. The characterization could help in data interpretation and in determining 
the true reasons for the success or failure of the agent or the method.  
Additionally, the current aerosol generation methods are not effective enough to 
atomize/nebulize protein aerosols. I learned this lesson from the limited cases of protein 
delivery in my experiment, the chemokine CXCL12 [chemokine (C-X-C motif) ligand 
12, EGF (epidermal growth factor), and insulin. Since the proteins used in this 
experiment were hard to purify, sold in small amounts, and cost a lot, the loss in the 
aerosol delivery system could not be afforded. Another concern with protein 
atomization/nebulization is how to maintain the protein activity. This also presents an 
interesting area to explore for future studies.  
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Appendix: Other Agents Evaluated in This Dissertation 
Work 
9.1 Single Agent 
9.1.1 Non-Steroidal Anti-Inflammatory Drugs 
Six NSAIDs (non-steroidal anti-inflammatory drugs, Table 9-1), including aspirin 
(ASA), naproxen, licofelone, celecoxib, piroxicam, and sulindac, were evaluated. All 
of them except celecoxib act as nonselective inhibitors of the enzyme cyclooxygenase 
(COX)-1 and COX-2, while celecoxib is a selective COX-2 inhibitor. Each drug was 
nebulized by a custom-built Collison atomizer with a controlled liquid feeding (100 
μl/min controlled by a syringe pump). The exposure time is was 10 min, and flowrate 
was 1.0 L/min. The solution concentration is the same in molar/ml using 30 mg/ml 
sulindac as a standard because sulindac showed an inhibitory effects in a prior 
experiment. All other drugs except sulindac showed no inhibitory effect. There might 
be two reasons: 1) the molar concentration of the solution should vary based on their 
IC50; 2) the solvent control group had much fewer tumors than in normal conditions. 
An inflammation related pathway is an interesting approach to cancer prevention, and 
these agents should be re-assessed with a more thoughtful design if possible. 
  
Appendix: Other Agents Evaluated in This Dissertation 
137 
Table  9‐1  Efficacy  and  testing  conditions  of  aerosolized  NSAIDs  (non‐steroidal 
anti‐inflammatory drugs) using a post‐initiation protocol in female A/J mice   
Agents Administration 
Solution 
Concentration 
Carcinogen‡
Efficacy Complete 
Time Multiplicity Load 
ASA Aerosol 15 mg/ml B[a]P -38.6% -25.1% Aug. 2011
Naproxen Aerosol 19 mg/ml B[a]P -58.5% -20.6% Aug. 2011
Licofelone Aerosol 32 mg/ml B[a]P -11.8% 20.8% Aug. 2011
Celecoxib Aerosol 32 mg/ml B[a]P -34.0% -33.9% Aug. 2011
Piroxicam Aerosol 28 mg/ml B[a]P -38.6% -12.1% Aug. 2011
Sulindac 
Aerosol 15 mg/ml B[a]P 8.3% 44.9% Sep. 2010†
Aerosol 30 mg/ml B[a]P 6.1% 46.6% Aug. 2011
‡: Mice at 6 weeks of age received one dose of B[a]P (100 mg/kg body weight, i.p. injection). 
All the aerosol groups, in Aug. 2011 (the same below), shared the same aerosol control group. 
B[a]P  induced  an  average  of  3.73 ±  0.85  tumors/mouse, with  a  tumor  load of  0.77 ±  0.22 
mm3/mouse.   
†:  The  aerosol  control  group  for  sulindac  in  Sep.  2010  (the  same  below)  has  the  tumor 
multiplicity of 4.09 ± 0.62  tumors/mouse,  and  the  tumor  load of 0.78 ± 0.17 mm3/mouse. 
The exposure time is 8 min.   
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9.1.2 Other Inhibitors 
Table 9‐2 Efficacy and testing conditions of other inhibitors using a post‐initiation protocol 
in female A/J mice   
Agents Administration 
Solution 
Concentration 
Carcinogen 
Efficacy  Complete 
Time Multiplicity Load 
Myo-inositol  Aerosol 8 min 
15 mg/ml 
B[a]P 
18.5% 41.3% Sep. 2010 
30 mg/ml 0.0% 53.3%* Sep. 2010 
Akt-1/2i Aerosol 10 min 20 mg/ml  B[a]P  -39.0% -4.7% Aug. 2011 
CDDO Aerosol 10 min 
2.5 mg/ml 
B[a]P 
-22.0% -31.6% Aug. 2011 
5 mg/ml 9.8% 62.4% Aug. 2011 
AZD6244 Aerosol 10 min 
5 mg/ml 
B[a]P 
17.3% 34.1% Aug. 2011 
10 mg/ml 21.9% 37.1% Aug. 2011 
SAHA Aerosol 15 min 
5 mg/ml 
B[a]P† 
33.5%* 42.9%* Oct. 2012 
10 mg/ml 6.3% 20.7% Oct. 2012 
Abbreviation: SAHA, suberoylanilide hydroxamic acid; B[a]P, benzo[a]pyrene.   
*: P < 0.05 
†: Mice received two doses of B[a]P (100 mg/kg body weight, i.p. injection), one week apart. 
Tumor multiplicity in the control group (Oct. 2012) was 16.60 ± 1.10 tumors/mouse, and the 
tumor load was 3.65 ± 0.36 mm3/mouse.   
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9.2 Combination Treatment 
9.2.1 Aerosolized Budesonide in Combination with Other Agents 
Aerosolized budesonide combined with six other agents, including polyphenon E 
(Chapter 6), indole-3-carbinol, pioglitazone, myo-inositol, targretin, and deguelin, 
were evaluated. Three combinations (Polyphenon E, indole-3-carbinol, and 
pioglitazone) were a continuance of the former bioassay. In the former assay, the 
efficacy of budesonide overpowered the effects of the other agents with which it was 
combined to the extent that no combination effects were observed. When the 
combination groups were repeated, the dose of every agent was reduced by half in 
hope that its efficacy could also be cut by half. However, the results of combinations 
with dietary I3C and pioglitazone (by gavage) were disappointing. The efficacy of 
budesonide was only slightly weakened compared with that in the former assay (78.4% 
of tumor load by 2 mg/ml budesonide, Fu et al., 2010).  
For the other three combinations, each single agent, myo-inositol, targretin, and 
deguelin, showed significant inhibitory effects. However, there was no combination 
effect when they were combined with budesonide. Either budesonide counteracts the 
efficacy of the other agent, or the dose of each agent was not optimal. These guesses 
need supportive data from mechanistic studies.  
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Table  9‐3  Efficacy  and  testing  conditions  of  aerosolized  budesonide  in  combinations with 
other agents 
Agents Administration Concentration Carcinogen 
Efficacy Complete  
Time Multiplicity Load 
Budesonide Aerosol 2 min 1.125 mg/ml B[a]P 51.1% 64.1%* Sep. 2010 
I3C Diet 5 μmol/g B[a]P 8.8% 15.5% Sep. 2010 
Budesonide + 
I3C 
Aerosol 2 min  
+ Diet 
1.125 mg/ml + 
5 μmol/g 
B[a]P 40.8% 46.2% Sep. 2010 
Pioglitazone Gavage 5 mg/ml B[a]P 8.8% 15.5% Sep. 2010 
Budesonide + 
Pioglitazone 
Aerosol 2 min  
+ Gavage 
1.125 mg/ml + 
5 mg/kg 
B[a]P 39.3% 57.4% Sep. 2010 
Myo-inositol Aerosol 8 min 30 mg/ml B[a]P 0.0% 53.3%* Sep. 2010 
Budesonide + 
myo-inositol 
Aerosol 2 min  
+ Aerosol 8 min 
1.125 mg/ml + 
30 mg/ml 
B[a]P 45.0% 77.3%* Sep. 2010 
Targretin Aerosol 8 min 10 mg/ml B[a]P 20.5% 58.5%* Aug. 2011 
Budesonide + 
Targretin 
Aerosol 2 min + 
Aerosol 8 min 
1.125 mg/ml + 
10 mg/ml 
B[a]P 42.2% 63.2%* Sep. 2010 
Deguelin Aerosol 8 min 1 mg/ml B[a]P 4.2% 56.3%* Aug. 2011 
Budesonide + 
Deguelin 
Aerosol 2 min + 
Aerosol 8 min 
1.125 mg/ml + 
1 mg/ml 
B[a]P 45.0% 62.2%* Sep. 2010 
Abbreviation: I3C, indole‐3‐carbinol.   
*: P < 0.05. 
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9.2.2 Aerosolized Gefitinib in Combination with Other Agents 
Table 9‐4 Efficacy and testing conditions of aerosolized gefitinib in combination with other 
agents 
Agents Administration Concentration Carcinogen 
Efficacy Complete  
Time Multiplicity Load 
Gefitinib Aerosol 15 min 15 mg/ml B[a]P 26.8% 54.8% Aug. 2011 
CDDO Aerosol 10 min 2.5 mg/ml B[a]P -22.0% -31.6% Aug. 2011 
Gefitinib + 
CDDO 
Aerosol 15 min + 
Aerosol 10 min 
15 mg/ml + 
2.5 mg/ml 
B[a]P 12.2% 48.7% Aug. 2011 
AZD6244 Aerosol 10 min 5 mg/ml B[a]P 17.3% 34.1% Aug. 2011 
Gefitinib + 
AZD6244 
Aerosol 15 min+ 
Aerosol 10 min 
15 mg/ml + 
5 mg/ml 
B[a]P 43.9% 65.6% Aug. 2011 
Gefitinib Aerosol 15 min 15 mg/ml B[a]P 49.8%*** 57.0%*** Oct. 2012 
Wortmannin Aerosol 10 min 2 mg/ml B[a]P 66.7%** 80.4%*** Oct. 2012 
Gefitinib + 
Wortmannin 
Aerosol 15 min + 
Aerosol 10 min 
15 mg/ml +  
2 mg/ml 
B[a]P 74.4%****v 76.7%**** Oct. 2012 
Rapamycin Aerosol 15 min 15 mg/ml B[a]P 50.6%*** 56.1** Oct. 2012 
Gefitinib + 
Rapamycin 
Aerosol 15 min 
+ Aerosol 15 min 
15 mg/ml +  
2 mg/ml 
B[a]P 41.1%** 39.2%* Oct. 2012 
*: P < 0.05; **: P < 0.001; ***: P < 0.0001; ****: P < 0.00001. 
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9.2.3 Other Combinations 
Table 9‐5 Efficacy and testing conditions of other combinations 
Agents Administration Concentration Carcinogen 
Efficacy Complete  
Time Multiplicity Load 
Rapamycin Aerosol 8 min 1 mg/ml B[a]P 20.0% 28.2% Sep. 2010 
3BrPA Aerosol 8 min 5 mg/ml B[a]P 55.5% 70.5%* Sep. 2010 
Rapamycin + 
3BrPA 
Aerosol 8 min+ 
Aerosol 8 min 
1 mg/ml + 
5 mg/ml 
B[a]P 41.3% 60.3% Sep. 2010 
DFMO Aerosol 8 min 15 mg/ml B[a]P 64.5%* 26.9% Sep. 2010 
Sulindac Aerosol 8min 15 mg/ml B[a]P 8.3% 44.9% Sep. 2010† 
DFMO + 
Sulindac 
Aerosol 8 min+ 
Aerosol 8min 
15 mg/ml + 
15 mg/ml 
B[a]P 12.5% 16.7% Sep. 2010 
Pioglitazone Gavage 10 mg/kg B.W. B[a]P 19.3% 43.1% Oct. 2012 
2-DG Aerosol 15 min 50 mg/ml B[a]P 36.0%* 40.8%* Oct. 2012 
Pioglitazone + 
2-DG 
Gavage + 
Aerosol 15 min 
10 mg/kg B.W. + 
50 mg/ml 
B[a]P -28.7% -24.9% Oct. 2012 
Abbreviations:  3BrPA:  3‐Bromopyruvate  acid;  DFMO,  difluoromethylornithine;  2‐DG, 
2‐deoxy‐D‐glucose; B.W., body weight. *: P < 0.05. 
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9.3  Intranasal delivery of interleukin 17A to prevent primary lung 
tumors 
 
Figure 9‐1 Treatment protocol of interleukin 17A 
Mice in Group 1 received an early treatment, two weeks after the second B[a]P 
injection. Mice in Group 2 received a late treatment, two weeks before the termination 
of the experiment. The efficacy of intranasally-delivered interleukin 17A was first 
compared with the IgG control group, and compared between the two treatment 
groups. The control groups received four times of treatment, while each of the 
treatment group receives twice treatment. This design is conservative because the 
control group had more stress from the dripping treatment than the treatment groups, 
which may negatively influence the tumor growth. The results were presented 
in Table 9-6. 
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Table 9‐6 Efficacy and testing conditions of intranasally‐delivered interleukin 17A (IL 17A) 
Agents Administration Concentration Carcinogen 
Efficacy Complete  
Time Multiplicity Load 
IgG Control 
Intranasal 
dripping (30 μl) 
0.1 mg/ml B[a]P - - Oct. 2012 
IL17A-Early 
Intranasal 
dripping (30 μl) 
0.1 mg/ml B[a]P 16.7% 49.3% Oct. 2012 
IL17A-Late 
Intranasal 
dripping (30 μl) 
0.1 mg/ml B[a]P -0.5% 40.5% Oct. 2012 
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